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FIGURE 4 
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SMALL MOLECULE DRUG RELEASE FROM 
IN SITU FORMING DEGRADABLE 
SCAFFOLDS INCORPORATING 
HYDROGELS AND BIOCERAMIC 
MICRO PARTICLES 
RELATED APPLICATIONS 
This application claims priority to U.S. Provisional Patent 
Application 61/975,139, filed 4 Apr. 2014, which is hereby 10 
incorporated by reference in its entirety. 
GOVERNMENT INTEREST 
2 
provides an injectable system for recovering bone or peri-
odontal tissue that provides for sustained drug delivery with 
structural support. 
SUMMARY OF THE INVENTION 
The present invention provides an injectable system for 
assisting in osseous tissue repair, the system comprising a 
degradable matrix in a solvent, a hydrogel and a ceramic. 
The degradable matrix may be selected from PLGA, poly 
(lactic acid) and poly(E-caprolactone). The ceramic may be 
selected from the group consisting ofhydroxyapatite (HA), 
brushite, calcium polyphosphate, ~-tricalcium phosphate, 
and monetite. PLGA may comprise different L:G ratios, 
This invention was made with Government support from 
National Institutes of Health grant AR060964 and National 
Science Foundation grants EPS-0814194 and DGE-
0653710. The Government may have certain rights in the 
invention. 
15 such as between 50:50 to 95:5, further up to 100:0 to include 
poly( acetic acid) or 0: 100 for poly(glycolic acid. PLGA may 
comprise a molecular weight range between 5 and 300 kDa 
and an endcap of carboxylate or an ester-linked hydrocar-
bon. The hydrogel may be selected from the group consist-
TECHNICAL FIELD 
The present invention relates generally to injectable scaf-
folds for sustained drug delivery in recovering tissues, such 
as bone and the periodontium. 
20 ing of poly(~-amino ester) (PBAE), methoxy poly( ethylene 
glycol)-poly(lactic-co-glycolide ), poly( ethylene glycol)-
poly(lactic-co-glycolide )-poly( ethylene glycol), alginate 
hydrogels, and hyaluronan hydrogels-poly(lactic-co-valero-
lactone ). The solvent may be selected from the group 
25 consisting of N-methyl-2-pyrrolidone, dimethyl sulfoxide, 
ethyl acetate, ethyl benzoate, and triacetin. 
BACKGROUND In certain embodiments, the injectable system may com-
prise between 15 and 45 w/w % as the degradable matrix and 
between 15 and 45 w/w % (+/-10%) as the ceramic and In situ forming implants ("ISis") have been investigated 
primarily for injection into soft tissue for sustained drug 
delivery (Hatefi A, Amsden B. Biodegradable injectable in 
situ forming drug delivery systems. Journal of Controlled 
Release 2002; 80(1-3):9-28). These systems were conceived 
due to the phase separation observed when a hydrophobic 
polymer dissolved in a water-miscible organic solvent is 
introduced to an aqueous environment, resulting in solidi-
fication of the polymer matrix (Shah NH, Railkar AS, Chen 
30 between 3-25 w/w % (+/-10%) as the hydrogel. In other 
embodiments, the injectable system may comprise 193 w/w 
% degradable matrix, 45.5 w/w % solvent, 30 w/w % 
ceramic and 5 w/w % drug-loaded hydrogel. In yet further 
embodiments, the injectable system may comprise 18 w/w 
35 % degradable matrix, 42 w/w % solvent, 30 w/w % ceramic 
and 10 w/w % drug-loaded hydrogel. 
F C, Tarantino R, Kumar S, Murjani M, Palmer D, Infeld M 
The hydrogel may be pre-loaded with a therapeutic agent. 
For example, the therapeutic agent may be selected from the 
group consisting of coldronate, alendronate, etidronate, 
40 zoledronate, simvastatin, lovastatin, rosuvastatin, SVAK-12, 
bone morphogenetic proteins, parathyroid hormone (1-34), 
metronidazole, doxycycline, vancomycin, gentamycin, cip-
rofloxacin, ketoprofen, celecoxib, diclofenac, meloxicam or 
H, Malick A W. A biodegradable injectable implant for 
delivering micro and macromolecules using poly(lactic-co-
glycolic) acid (PLGA) copolymers. Journal of Controlled 
Release 1993; 27(2):139-147), By mixing drugs into the 
polymer phase prior to injection, a drug-loaded, solid depot 
can form upon injection into the body. Such systems are 
available in FDA-approved formulations, such as ATRI- 45 
DOX®, for delivery of doxycycline into gum tissue, and 
ATRIGEL®, which is approved for delivery of leuprolide 
acetate for treatment of prostate cancer. These systems 
provide prolonged drug release, with an initial burst depen-
dent on drug and solvent properties and a release period 50 
dependent on drug and polymer properties (Parent M, Nou-
vel C, Koerber M, Sapin A, Maincent P, Boudier A. PLGA 
in situ implants formed by phase inversion: Critical physi-
cochemical parameters to modulate drug release. Journal of 
Controlled Release 2013; 172(1):292-304). As such, these 55 
injectable systems avoid the additional trauma that would be 
needed for implantation of large, solid dosage forms. Fur-
thermore, the polymers are hydrolytically degradable, so 
there is no secondary surgery required to remove an implant 
after drug delivery is complete (Kenley R A, Lee M 0, 60 
Mahoney T R, Sanders L M, Poly(lactide-co-glycolide) 
decomposition kinetics in vivo and in vitro. Macromolecules 
1987; 20(10):2398-2403). Because these polymer systems 
are locally injectable and space-filling, they should be able 
to infiltrate and conform to complex geometries, such as a 65 
network of trabecular bone. However, these materials offer 
little in the way of structural support. The present invention 
mixtures thereof. 
The present invention also provides methods of preparing 
an in situ injectable system for osseous tissue, comprising 
mixing a hydrogel, a ceramic and a degradable matrix. The 
hydrogel may be preloaded or be admixed at the point of 
care with at least one pharmaceutical agent. The degradable 
matrix may be further cross-linked. The hydrogel may be 
mixed with the degradable matrix prior to cross-linking. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows mechanical properties of cylindrical scaf-
folds prepared with different MHA content and tested at 
multiple strain rates. A) Compressive modulus. B) Yield 
stress. Data are grouped by displacement rate and ordered by 
increasing MHA content. Shared letters denote statistical 
similarity, and columns without a single shared letter are 
significantly different. Data are mean±standard deviation 
(n=3). 
FIG. 2 shows representations of viscosity and mechanical 
properties for scaffolds containing various hydrogel 
microparticle content, formulated with 30% total NHA and 
the remainder of the weight composed of 30% PLGA in 
NMP. Shared letters denote statistical similarity, and col-
US 10,682,442 B2 
3 
umns without a single shared letter are significantly differ-
ent. Data are mean±standard deviation (n=3). 
FIG. 3 shows, using SAWBONES® open cell rigid poly-
urethane foams made to mimic trabecular bone architecture, 
two 5x5x5 mm3 samples with and without the mixture 5 
injected, demonstrating the space-filling capability of the 
mixture. The samples receiving injections were immersed in 
buffer for 3 days to ensure complete solidification of the 
PLGA. Also included are graphs showing mechanical prop-
erties of Sawbones injected with varying weight percentages 10 
of NHA and MHA. Again, 30% NHA provided the most 
benefit, and 15% NHA/15% MHAwere comparable. Modu-
4 
change expressed as a fraction of pre-injection mass (n=3). 
B) Non-destructive mass loss showing total hydrated scaf-
fold mass change, expressed as a fraction of pre-injection 
volume (n=5). Data are mean±standard deviation. 
FIG. 12 shows representative microCT cut-plane images 
of lyophilized scaffolds showing internal microarchitecture 
throughout the degradation process. Scale bars are 1 mm. 
FIG. 13 shows morphometric parameters during degra-
dation. A) Porosity and B) average pore size measured by 
microCT evaluation of samples through 35 days. 
FIG. 14 shows mechanical properties of scaffolds pre-
pared with different MHA:NHA ratios, grouped by increas-
ing total HA content (w/w %) and subsequently ordered by 
increasing MHA content (w/w %). A) Compressive modu-
lus is lower than pure scaffolds due to imperfect geometry 
and the inferior mechanical properties of the Sawbones 
themselves. 15 !us. B) Yield stress. Shared letters denote statistical similar-
ity, and columns without a single shared letter are signifi-
cantly different. Data are mean±standard deviation (n=3). 
FIG. 4 shows PBAE particles, with unbound HA 
microparticles (black arrows) and PBAE hydrogel (white 
arrows) labeled. HA particles can also been seen coating the 
PBAE particles. At the highest magnification, HA micropar-
ticles can be seen to be composed of aggregated nanopar- 20 
ticles. 
FIG. 5 shows composite PBAE particles, with homoge-
neous distribution of HA throughout particles. HA and 
PBAE are indistinguishable, though at higher magnification, 
spherical nanostructures can be seen all over the surface of 25 
the material. Because PBAE was polymerized around HA, 
there is no discrete HA powder visible, and all HA content 
is encased in polymer, which supports the superior drug 
loading properties of these composite microparticles. 
FIG. 6 shows PBAE microparticle and injectable scaffold 30 
fabrication process. A) Technique for formation of PBAE 
hydrogels and processing them into drug-containing pre- or 
post-loaded microparticles. B) Comparison of a traditional 
injectable PLGA system (right) to the proposed system 
(left). 35 
FIG. 7 shows drug loading into PBAE hydrogel. A) 
Simvastatin loading after soaking in 100% ethanol solutions 
for 24 hours. B) Loading after soaking in 50% ethanol 
clodronate solution for 24 hours. C) Loading after immer-
sion in aqueous clodronate solution for 24 hours. Data are 40 
mean±standard deviation (n=3). 
FIG. 8 shows morphology, composition, and swelling of 
PBAE microparticles. A) SEM image of a PBAE micropar-
ticle, with EDS performed on the highlighted portion. B) 
Top left: Region chosen from (A) for EDS analysis, with 45 
arrows indicating points of spectral analysis performed in 
(C). Bottom left: Composite overlay of calcium and phos-
phorous on that region. Top right: EDS detection of calcium. 
Bottom right: EDS detection of phosphorous. B). C) EDS 
spectra of an HA particle (upper right) and PBAE (lower 50 
right). D) PBAE swelling kinetics expressed as a percentage 
of mass increase in injection mixture (30 wt % HA mixed 
into 20% PLGA solution). Data are mean±standard devia-
tion (n=3). 
FIG. 9 shows surface vs. bulk loading in microparticles: 55 
A) simvastatin post-loaded, C) simvastatin pre-loaded, and 
E) clodronate pre-loaded. Loading efficiency: B) post-
loaded simvastatin, D) pre-loaded simvastatin, and F) pre-
loaded clodronate. Data are mean±standard deviation (n=3). 
FIG. 10 shows cumulative release profiles. A) Release of 60 
simvastatin loaded freely into the PLGA solution with (fl) or 
without HA ( o ), or loaded into PBAE (□) (n=3). B) Release 
of clodronate freely loaded into PLGA solution with (fl) or 
without HA ( o ), or loaded into PBAE microparticles (□) 
(n=4). Data are mean±standard deviation. 
FIG. 11 shows degradation of in situ forming PLGA 
scaffolds. A) Destructive mass loss showing dry mass 
65 
FIG. 15 shows injectability of 30% NHA scaffold mix-
tures prepared with varying PBAE microparticle content. A) 
Representative graph of collected force (green curve, left 
axis) and displacement (blue curve, right axis) data, with the 
highlighted linear portion of the displacement used to cal-
culate volumetric flow rate. B) Time required to inject 0.5 
mL from a 16 gauge needle for various injection forces and 
PBAE microparticle contents. The dotted lines indicate 
reasonable limits for injection time for 0.5 mL (60 sec) and 
injection force (50 N). Data are mean±standard deviation 
(n=3). 
FIG. 16 shows SEM images of 30% w/w NHA scaffold 
microarchitecture, showing A) macropores on the order of 
100 µm (white arrows), B) microporous PLGA substructure, 
C) elongated pores perpendicular to the surface ( dotted 
arrows), and D) NHAnanoparticles embedded in the PLGA 
matrix (black arrows). 
FIG. 17 shows microCT analysis of scaffolds prepared 
with varying NHA and MHA content, showing A) porosity 
and B) material density of cylindrical samples. Data are 
grouped by total HA content, and ordered by increasing 
NHA content. Shared letters denote statistical similarity, and 
columns without a single shared letter are significantly 
different. Data are mean±-standard deviation (n=3). 
FIG. 18 shows microstructural and mechanical properties 
of trabecular bone samples from porcine humeral heads with 
or without injection of 30% NHA/5% PBAE scaffolds. A) 
MicroCT cutplane of humeral head prior to injection (left) 
and post-injection (right). B) Cylindrical bone sample con-
taining solidified scaffold. C) Compressive modulus. D) 
Yield stress. Data are mean±-standard deviation (n=7). 
*Significantly different from Control (p<0.001). **Signifi-
cantly different from Control (p<0.01). Scale bar is 5 mm. 
FIG. 19 shows mass loss of ISis. Remaining dry mass of 
A) HMW scaffolds and C) LMW scaffolds. Remaining wet 
mass ofB) HMW scaffolds and D) LMW scaffolds. Data are 
mean±standard deviation (n=3). 
FIG. 20 shows bisected microCT reconstructions of 
HMW ISis containing no additives (Control) or 10% PBAE 
particles (H, AH, or H/ AH). White indicates material present 
in the cut plane. Arrows indicate solid material within pores. 
FIG. 21 shows microarchitecture of HMW scaffolds 
throughout degradation. A) Porosity and B) mass-normal-
ized volume of scaffolds, evaluated using microCT. Acces-
sibility of C) scaffold volume and D) mass-normalized 
surface area to a simulated 24 µm sphere. Data are 
mean±standard deviation (n=3). 
FIG. 22 shows interfacial strength measured from push-
out tests on cylindrical samples within gelatin molds. Data 
are mean±standard deviation (n=3). 
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FIG. 23 shows mechanical properties of cylindrical 
implants subjected to 30 cycles of 1 % compressive strain at 
6 
1 Hz. A) Initial and 30-cycle modulus. B) Ratio of initial to 
30-cycle modulus. C) Initial and 30-cycle resilience. D) 
Ratio of initial to 30-cycle resilience. Data are 5 
mean±standard deviation (n=3). 
reinforced in situ forming PLGA systems for intraosseous 
injection, J. Biomed. Mater. Res. Part A, doi: 10.1002/ 
jbm.a.35375; Fisher, P. D., Clemens, J., Hilt, J. Z., and 
Puleo, D. A. (2015). Multifunctional poly(~-amino ester) 
hydrogel microparticles in periodontal in situ forming drug 
delivery systems (in review); Fisher, P. D., Milbrandt, T. M., 
FIG. 24 shows simvastatin release from A) HMW and B) 
LMW scaffolds. D+S indicates that scaffolds were co-loaded 
with simvastatin and doxycycline. Data are mean±standard 
deviation (n=3). 
FIG. 25 shows doxycycline release from A) HMW and B) 
LMW ISis. D+S indicates that scaffolds were co-loaded with 
simvastatin and doxycycline. Pre indicates that doxycycline 
was pre-loaded into PBAE microparticles. Data are 
mean±standard deviation (n=3). 
DESCRIPTION 
Controlled drug delivery systems offer a variety of poten-
tial advantages over traditional routes of administration, 
such as oral dosages and intravenous or subcutaneous injec-
tion of drug solutions, due to their spatial and temporal 
control over drug release (Allen T M, Cullis P R. Drug 
Delivery Systems: Entering the Mainstream. Science 2004; 
303:1818-22). Traditional dosage forms result in systemic 
circulation of drug, and the oral route is also subject to 
first-pass metabolism (Veber D F, Johnson SR, Cheng H-V, 
Smith B R, Ward K W, Kopple K D. Molecular Properties 
That influence the Oral Bioavailability of Drug Candidates. 
Journal of Medicinal Chemistry 2002; 45:2615-23). Injec-
tions introduce a bolus of drug at high concentrations, and 
long-term treatment requires repeated dosing, resulting in 
pulsatile concentration profiles (Uhrich K E, Cannizzaro S 
M, Langer R S, Shakesheff K M. Polymeric systems for 
controlled drug release. Chemical reviews 1999; 99:3181-
98). Implantable drug-loaded scaffolds can be placed at the 
treatment site to minimize systemic exposure and can be 
designed to control release kinetics by varying the chemical 
and physical nature of the carrier (Uhrich K E, Cannizzaro 
S M, Langer R S, Shakesheff K M. Polymeric systems for 
controlled drug release. Chemical reviews 1999; 99:3181-
98; Garg T, Singh 0, Arora S, Murthy R. Scaffold: a novel 
carrier for cell and drug delivery. Critical reviews in thera-
peutic drug carrier systems 2012; 29:1-63). These systems, 
however, generally require a surgical procedure to implant 
the device, and in the case of a non-degrading material, 
require a removal surgery. As a result, significant effort in 
the drug delivery field has focused on injectable, biodegrad-
able drug carriers, such as in situ gelling, polymerizing, or 
precipitating systems (Hatefi A, Amsden B. Biodegradable 
injectable in situ forming drug delivery systems. Journal of 
Controlled Release 2002; 80:9-28; Packhaeuser C B, 
Schnieders J, Oster CG, Kissel T. In situ forming parenteral 
drug delivery systems: an overview. European Journal of 
Pharmaceutics and Biopharmaceutics 2004; 58:445-55). A 
space-filling scaffold capable of forming into a biodegrad-
able solid at the treatment site is an appealing option because 
Hilt, J. Z., and Puleo, D. A. (2013). In situ forming drug 
delivery scaffold for treating avascular necrosis of the femo-
ral head. Presented at the 2013 Annual Meeting of the 
10 Society For Biomaterials, April 10-13, Boston, Mass.; 
Fisher, P. D., Milbrandt, T. M., Hilt, J. Z., and Puleo, D. A. 
(2014). Drug release and mechanical effects of poly(~-
amino ester) and hydroxyapatite on in situ forming PLGA 
systems. Presented at the 2014 Annual Meeting of the 
15 Society For Biomaterials, April 16-19, Denver, Colo.; 
Fisher, P. D., Milbrandt, T. M., Hilt, J. Z., and Puleo, D. A. 
(2014). Improving properties of in situ forming PLGA 
implants via poly(~-amino ester) and hydroxyapatite addi-
tives. Presented at the 2014 Annual Meeting of the Bio-
20 medical Engineering Society, October 22-25, San Antonio, 
Tex.; Fisher, P. D., Milbrandt, T. M., Hilt, J. Z., and Puleo, 
D. A. (2015). An in situ forming, injectable PLGA compos-
ite for orthopedic applications. To be presented at the 2015 
Annual Meeting of the Society For Biomaterials, April 
25 15-18, Charlotte, N.C. 
The present invention provides a system for delivery of 
therapeutic and structural support into bone, joint and peri-
odontal sites. The system of the present invention provides 
a composition comprised of a degradable matrix, a ceramic, 
30 and a hydrogel in a solvent. Suitable degradable matrices 
may include, but are not limited to: PLGA with different L:G 
ratio, molecular weight, and endcap; poly(lactic acid); and 
poly( E-caprolactone ); suitable ceramics may include, but are 
not limited to: hydroxyapatite (HA), brushite, calcium poly-
35 phosphate, ~-tricalcium phosphate, and monetite; suitable 
hydrogels may include, but are not limited to: poly(~-amino 
ester) (PBAE), methoxy poly(ethylene glycol)-poly(lactic-
co-glycolide ), poly( ethylene glycol)-poly(lactic-co-gly-
colide )-poly( ethylene glycol), alginate hydro gels, and 
40 hyaluronan hydrogels; and suitable solvents may include, 
but are not limited to: N-methyl-2-pyrrolidone (NMP), 
dimethyl sulfoxide, ethyl acetate, ethyl benzoate, and tri-
acetin. Hydrogels may be preloaded with a pharmaceutical 
agent or admixed by a practitioner just prior to injection of 
45 the system. 
The system of the present invention may be injected into 
different sites and may further incorporate multiple thera-
peutic agents. Accordingly, the system can be utilized in 
procedures requiring improved structural support with the 
50 added benefit of in situ sustained drug delivery. For example, 
the present invention may be utilized in dental, craniofacial, 
and orthopedic applications. These include adult avascular 
necrosis of bone, large bone segmental defects resulting 
from trauma, hip and knee replacement revision with bone 
55 loss, reconstruction following bone tumor resection, and 
treatment of periodontal defects. 
The system of the present invention may further include 
a therapeutic agent or more thereof within the hydrogel or 
the matrix itself. Suitable therapeutic agents may comprise 
60 agents for decreasing inflanimation, increasing osteogenesis, 
preventing resorption and preventing infection. These 
include, but are not limited to the following. 
it can penetrate a tissue network to deliver drugs at a fixed 
location with minimal invasiveness and no removal surgery. 
Additional background for the present invention can be 
found as follows: Fisher, P. D., Palomino, P., Milbrandt, T. 
M., Hilt, J. Z., and Puleo, D. A. (2014). Improved small 
molecule drug release from in situ forming polylactic-co-
glycolic acid) scaffolds incorporating poly(~-amino ester) 
and hydroxyapatite microparticles, J. Biomater. Sci. Polym. 65 
Ed. 25:1174-1196; Fisher, P. D., Venugopal, G., Milbrandt, 
Antiresorptive: clodronate, alendronate, etidronate, and 
zoledronate 
Osteogenic: simvastatin, lovastatin, rosuvastatin, SVAK-
12, bone morphogenetic proteins, and parathyroid hor-
mone (1-34) T. A., Hilt, J. Z., and Puleo, D. A. (2015). Hydroxyapatite-
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Antimicrobial: metronidazole, doxycycline, vancomycin, 
gentamycin, and ciprofloxacin 
Anti-inflammatory: ketoprofen, celecoxib, diclofenac, 
and meloxicam 
The system of the present invention offers improved 5 
release kinetics, multiple release profiles, and rapid solidi-
fication compared to traditional in situ forming implants 
(IS Is). Incorporating drug-loaded microparticles into an 
injectable degradable matrix system may provide a second-
ary means of controlling release kinetics. Intraosseous injec- 10 
tion in particular is a suitable application for the in situ 
forming system of the present invention due to the inter-
connected porous network of the trabecular bone that makes 
placement of pre-formed scaffolds difficult and removal 
surgery impossible. The injectable degradable systems can 15 
accommodate filler particles such as bioceramics, such as 
hydroxyapatite (HA), to influence microarchitecture, 
mechanical properties, or osteoconductivity. 
Those skilled in the art will appreciate that the physical 
characteristics of the system can be varied by altering the 20 
concentrations of each component within the system. While, 
the composition of the system can be varied significantly, 
attention should include focus on resulting effects on drug 
content, mechanical properties, and "injectability". One 
embodiment of the present invention provides for 30 w/w % 25 
(+/-15%) of the degradable matrix in solvent (solvent 
provides 30-60 w/w %); 30 w/w % ( +/-10%) of the biocer-
amic particles and 5-10 w/w % (+/-10%) of the hydrogel 
particles. For example, the system may comprise a 30 w/w 
% PLGA solution in NMP, 30 w/w % HA nanopowder and 30 
3-20% w/w % PBAE microparticles (depending on desired 
drug loading; 10% PBAE does not affect mechanical prop-
erties but does increase viscosity, which makes the solution 
more difficult to inject). 
For example, in one embodiment, the system may com- 35 
prise, by weight: 
19.5% degradable matrix (e.g. PLGA) 
45.5% solvent (e.g. NMP) 
30% bioceramic (e.g. HA nanopowder) 
8 
formulation a good mechanical match for the proposed 
system. FIG. 1 shows a graph of modulus (A) and yield 
stress (B) as a function of HA content. 
Increasing hydrogel content increases viscosity almost 
exponentially, while mechanical properties are unaffected 
until 15% (by weight). By varying hydrogel content, a 
thicker or thinner mixture can be formulated with little to no 
mechanical implications. A more viscous injectable may be 
suitable for larger defects or more osteoporotic bone, since 
the paste will begin to solidify before it can escape the 
injection site. A less viscous formulation is suitable for 
collapsed bone or for regions of trabecular bone with lower 
pore size, since the injection rate can be maximized to fill 
dense trabecular networks. FIG. 2 shows representations of 
viscosity and mechanical properties for scaffolds containing 
various hydrogel microparticle content, formulated with 
30% total NHA and the remainder of the weight composed 
of 30% PLGA in NMP. 
The injectable system of the present invention can fill 
complex geometry, such as trabecular bone. FIG. 3 illus-
trates, using SAWBONES® open cell rigid polyurethane 
foams made to mimic trabecular bone architecture, two 
5x5x5 mm3 samples with and without the mixture injected, 
demonstrating the space-filling capability of the mixture. 
The samples receiving injections were immersed in buffer 
for 3 days to ensure complete solidification of the PLGA. 
Also included are graphs showing mechanical properties of 
SAWBONES® injected with varying weight percentages of 
NHA and MHA. Again, 30% NHA provided the most 
benefit, and 15% NHA/15% MHA were comparable. Modu-
lus is lower than pure scaffolds due to imperfect geometry 
and the inferior mechanical properties of the Sawbones 
themselves. 
The system of the present invention can be adapted for a 
variety of intraosseous treatments, with properties tuned to 
fit the application. Both adult and pediatric avascular necro-
sis are targets for this treatment, and the drug content, 
viscosity, and mechanical properties can be modified appro-
priately. In addition, compression fractures and bone cysts 
5% drug-loaded hydrogel (e.g. PBAE microparticles) 
Such compositions provide the advantage of a low viscosity 
and higher injectability, but offer reduced capacity for drug 
loading. 
40 are other applications for such a system where local 
intraosseous delivery, space-filling, and solidification of a 
drug delivery matrix are needed. 
In another embodiment, the system may comprise, by 
Those skilled in the art will appreciate that the bioceramic 
particles can be mixed with the matrix either prior or post 
weight: 
18% degradable matrix (e.g. PLGA) 
42% solvent (e.g. NMP) 
30% bioceramic (e.g. HA nanopowder) 
45 cross-linking of the hydrogel. For example, bioceramics, 
such as HA, can be mixed with a hydrogel, such as PBAE, 
prior to cross-linking. Recent research has explored a new 
composite ceramic-hydrogel microparticle instead ofhydro-
10% drug-loaded hydrogel (e.g. PBAE microparticles) 
Such compositions provide the advantage of increased drug 50 
loading but with a high viscosity/lower injectability. Increas-
ing the hydrogel microparticle content to 15% or higher has 
demonstrated a negative effect on mechanical properties. 
In general, increasing bioceramic content increases com-
pressive modulus and yield stress to up until approximately 55 
30% of the total weight of the system, and after such has 
either negative or no effect on these properties. 
The system may further provide for a mixture of biocer-
amics. For example, generally, nano-HA (NHA) demon-
strated more benefit than micro-HA (MHA) at equivalent 60 
concentrations, and NHA also provided the largest maxi-
mum compressive moduli and yield stresses. However, one 
of the highest compressive moduli was observed at 30% 
NHA content and with a mixture containing 15% MHA and 
15% NHA, both of which provided similarly high proper- 65 
ties. The compressive modulus of a 30% NHA mixture was 
comparable to that of trabecular bone, making a 30% NHA 
gel microparticles coated with ceramic, creating composite 
ceramic-hydrogel sheets that can be easily ground into 
microparticles without requiring additional ceramic as a 
dispersant. This technique provide several advantages: 
1. Composite particles retain virtually all therapeutic 
agent ( e.g. simvastatin) (99%) after a surface wash with 
buffer, while previous particles retained approximately 
50%. This can be attributed to absence of bioceramic 
aggregates, which can loosely adsorb drug that ends up 
washed off. Further, composite particles have a homo-
geneous distribution, e.g. of micro- and nanoscale HA 
particles, throughout the particle volume (see FIG. 4), 
so therapeutics should be retained within particles 
rather than loosely bound to free HA. 
2. Composite particles contain a relatively higher hydro-
gel content (33 w/w % vs 25 w/w %). This allows of 
higher drug loading with equivalent hydrogel content, 
which can either increase total drug dose or reduce the 
viscosity of the injectable mixture at equivalent doses. 
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3. The fabrication process of composite particles leads to 
bioceramic particles uniformly distributed throughout 
the composite particle volume, while the previous 
technique resulted in bioceramic aggregates primarily 
on the surface of particles, as well as bioceramic 5 
aggregates unbound to any hydro gel. These micro struc-
tural differences are illustrated in the SEM images of 
FIG. 4. 
the physical constraint within the matrix, there is enough of 
an effect to provide 4 to 10-fold higher interfacial strength 
than controls. 
A further benefit of the present invention lies in that a 
scaffold that expands to fill its injection site as it solidifies is 
less likely to cause irritation due to movement within the 
pocket. Furthermore, more contact area between the implant 
and the tissue means that the released drug has a shorter path 
to enter the target tissue, and it has a smaller likelihood of The examples described below demonstrate varying 
loaded therapeutic agents within the system, as well as 
mechanical properties and the overall texture and viscosity 
10 being washed away. This swelling-based, space-filling 
approach is an alternative to other avenues that seek to 
reduce detachment by improving the adhesion between the 
polymer surface and surrounding tissue. 
to allow for injection. In general, increasing the bioceramic 
concentration, such as increasing micro-HA (MHA) or 
nano-HA (NHA) content, increases the system's compres-
sive modulus and yield stress (generally, NHA provides 
more benefit than MHA at equivalent concentrations, and 
NHA also provides the largest maximum compressive 
moduli and yield stresses). By varying the concentration of 
hydrogel present, such as PBAE content, a thicker or thinner 
mixture can be formulated with little to no mechanical 20 
The present hydrogel-containing matrices demonstrated 
15 improve pocket retention through a 15-day period as com-
pared to other studies using more adhesive components, 
which demonstrated increased bioadhesion in the first sev-
eral hours following injection into a simulated pocket (Do M 
P, Neut C, Delcourt E, Seixas Certo T, Siepmann J, Siep-
mann F. In situ forming implants for periodontitis treatment 
with improved adhesive properties. Eur J Pharm Biopharm implications. The injectable mixture is also capable of filling 
complex trabecular geometry. The system of the present 
invention can be adapted for a variety of intraosseous 
treatments, with properties tuned to fit the application. Both 
adult and pediatric avascular necrosis are conditions that can 
benefit from this system, and the drug content, viscosity, and 
mechanical properties can be modified appropriately. In 
addition, compression fractures and bone cysts are other 
applications for such a system where local intraosseous 
delivery, space-filling, and solidification of a drug delivery 
matrix are needed. 
The present invention provides for incorporating hydro gel 
microparticles into a degradable matrix to provide several 
new functions: mechanical support, porosity, space-filling, 
and controlled co-delivery of antibiotics and osteogenic 
drugs. Combining all these functions provides a more effec-
tive space-filling scaffold and offers improved release kinet-
ics compared to existing systems used. Further, the system 
of the present invention provides for acute antibiotic deliv-
ery accompanied by co-delivery of an antibiotic and an 
osteogenic agent with improved effects on swelling, degra-
dation, microarchitecture, and mechanical properties. (see, 
e.g., bisected microCT reconstructions (FIGS. 5 and 8). 
Hydrogel particle additives act as both porogens and drug 
delivery vehicles within the solid degradable matrix. Hydro-
gel microparticles also influence macro- and microstructural 
changes of the matrix as it degrades. Hydrogel micropar-
ticles further cause the degradable matrix to adopt a porous 
network microarchitecture with no difference between sur-
face or central pore sizes, because the homogeneous distri-
bution of hydrogel microparticles act as a template for 
uniform matrix precipitation. As set out in the examples, the 
lattice-like matrix network of hydrogel-containing implants 
provide sustained mechanical resilience even after the deg-
radation period of the matrix had passed. The increased 
porosity and accessible surface area ofhydrogel-containing 
degradable matrices offers many advantages when consid-
ering matrix functions as a potential scaffold rather than 
solely a drug delivery device. 
The swelling of hydro gels provides for improved space-
filling and pocket retention of implants. As set forth in the 
examples, even at an initial 3-day measurement, HMW-AH 
samples had significantly higher interfacial strength than 
controls, and this difference became even more pronounced 
as the incubation period increased. AH hydrogels were 
observed to swell beyond 200% of their initial mass within 
2 days in PBS, and while this effect is may be muted due to 
2014 88(2): 342-50). As set forth in the examples, PLGA 
deformed plastically and became stiffer under compression, 
even at low strains and only 30 compression cycles, while 
25 the modulus of HMW-AH samples remained unchanged, 
demonstrating that hydrogel PBAE additives preserve elas-
ticity. HMW-AH samples were less stiff and retained their 
modulus throughout cyclic compression, demonstrating that 
they are more suitable to withstand a dynamic mechanical 
30 environment. The lack of change for both modulus and 
resilience after cyclic loading with the present system pro-
vides for the development of more mechanically suitable 
implants. 
As described herein, in situ forming scaffolds according to 
35 the present invention were characterized to determine their 
mechanical properties, injectability, and microarchitecture. 
Strength was increased approximately three-fold, while 
compressive modulus was improved approximately 6-fold. 
Scaffolds retained a uniformly porous microarchitecture, 
40 and the bioceramic particles were distributed evenly 
throughout the matrix. Injectability remained within clini-
cally accepted standards. For example, ex vivo injections 
into intact porcine femoral heads increased compressive 
modulus of trabecular bone. The injectable scaffold of the 
45 present invention thus offers mechanical reinforcement 
coupled with drug delivery in a single injection for bone-
weakening conditions, such as osteonecrosis or osteoporo-
sis. 
An implant that acutely reinforces compromised bone, 
50 controls drug release, and gradually degrades to allow 
regeneration of native tissue can provide a comprehensive 
treatment in a single injection. Scaffolds with material 
properties similar to trabecular bone can aid load-bearing 
while the drug delivery component of the scaffold exerts its 
55 effect. It is important to consider these scaffolds as a means 
for temporary augmentation that can acutely preserve bone 
while treatment occurs, not as a replacement for healthy 
bone tissue. Injectability is a unique concern for in situ 
forming scaffolds, because both bioceramic and hydrogel 
60 particle additives increase viscosity. Because prior injectable 
degradable matrix systems were not intended for mechanical 
support, and drug is usually mixed freely into the polymer 
solution, viscosity has not been a limiting factor when 
designing these systems. However, injectable bone cements 
65 and fillers have encountered issues with injectability because 
they are composed of a liquid phase containing high con-
centrations of suspended particles (Bohner M, Baroud G. 
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Injectability of calcium phosphate pastes. Biomaterials 
2005; 26(13):1553-1563; Alves H L, Santos LA, Bergmann 
12 
implanted material improves the mechanical properties of 
bone to prevent collapse of damaged or diseased tissue, and 
the material degrades over the course of 6 weeks, which is 
an appropriate period to allow drug release and bone repair. 
The present invention also provides methods of using the 
system. The present invention provides for contacting or 
administering to a subject the system described herein. As 
described above, the system can be administered by injec-
tion. Those skilled in the art will appreciate that the consis-
C P. Injectability evaluation of tricalcium phosphate bone 
cement. J Mater Sci: Mater Med 2008; 19(5):2241-2246). 
The scaffold of the present invention demonstrated the 5 
capability of filling the bone tissue in all directions. Fur-
thermore, injected bone tissue was significantly stronger and 
stiffer than native tissue, suggesting that the filling that was 
achieved is sufficient to greatly improve mechanical prop-
erties of trabecular bone. 10 tency, viscosity and overall make up of the applied system 
will determine how the system is injected, affecting such 
parameters as rate of injection, as well as gauge of needle. 
Further parameters that can determine the rate of injection, 
Injectable scaffold mixtures are capable of being injected 
through a standard bone biopsy needle, infiltrating trabecu-
lar bone, then solidifying to produce scaffolds with mechani-
cal properties comparable to those of trabecular bone. This 
injectable scaffold offers a treatment platform for ailments 15 
requiring both drug delivery and mechanical reinforcement 
of trabecular bone, and it has the advantage of being easily 
injectable and fully resorbable. 
The scaffold of the present invention provides a space-
filling system that can bypass spatial limitations of fixed- 20 
form implants. Further, through investigating the present 
invention, while drugs showed burst release when freely 
mixed or encapsulated within gelatin microspheres, hydro-
gel particles allowed for more prolonged release. Scaffold 
porosity further is important to allow new bone ingrowth, 25 
and that the scaffolds will degrade over a period of months 
allows for accommodation of tissue regeneration. 
Bioceramic additives, such as hydroxyapatite, may 
improve mechanical properties and bind to dianionic drugs, 
such as bisphosphonates, to reduce initial burst. The addition 30 
of these particle types can create a system suitable for 
intraosseous injection due to the mechanical reinforcement 
and delivery of both osteogenic and anti-resorptive treat-
ments from a single injection. The ISI system containing 
drug-loaded hydrogel microparticles exhibited significantly 35 
reduced burst (81 % vs 39%) and extended release (95% 
release by 28 days vs 10 days). Compressive modulus and 
yield stress of cylindrical scaffolds increased up to 30 w/w 
% bioceramic. Additives were demonstrated to improve both 
release and mechanical properties of traditional ISis. Hydro- 40 
gel microparticles and bioceramics reduced the initial burst 
of drug release which may be suitable for intraosseous 
injection where a treatment period of weeks is preferable but 
rapid precipitation is required. Mechanical properties can be 
controlled by varying bioceramic content and particle size 45 
(e.g., nano may range from 5-10 nm to 100 nm, and micro 
may range from 0.1-250 µm) and the system was capable of 
space-filling throughout a trabecular bone-like sample and 
improving its mechanical properties, which can acutely 
salvage diseased or damaged bone while the drug release 50 
component takes effect. 
Bioceramics significantly increased the compressive 
modulus and strength of the material. Ex vivo injections 
resulted in good space-filling, and the injected material was 
constrained by the articular and metaphyseal cartilage 55 
boundaries. The addition of bioceramic particles enables in 
situ forming implants to be used in a variety of orthopedic 
applications because the mechanical properties can be 
adjusted simply by varying the bioceramic concentration 
and particle size. These composite scaffolds have a more 60 
homogeneous pore structure, and the high accessibility of 
these pores allows a greater surface area for potential cell 
access and tissue contact. The addition of bioceramics also 
allows these materials to be visualized during injection via 
fluoroscopy to ensure the target site is receiving the treat- 65 
ment, and the material rapidly solidifies and is effectively 
retained within the target tissue. Once solidified, the 
as well as the make of the applied system are the area of the 
subject to receive the system. Those skilled in the art will 
appreciate that certain applications will demand a slower 
solidifying system, while others demand a faster solidifying 
system. Further still, a subject may receive multiple injec-
tions in order to completely fill the area requiring application 
of the system. 
The present invention also provides methods for making 
the system. As described herein, the components of the 
system can be added together prior to injection within a 
subject. Those skilled in the art will appreciate that the time 
of adding the components altogether can be time sensitive as 
the fully assembled system will start to solidify. For the 
system described herein, solidification does not begin until 
the mixture comes into contact with an aqueous phase. 
Specifically, the system described herein offers the advan-
tage of indefinite handling time, and the setting time only 
begins post-injection. Further, as described herein the com-
ponents or parts thereof, can be mixed together prior to cross 
linking or post crosslinking. The components can be added 
together such that of the final system: 30 w /w % ( +/-15%) 
comprises the degradable matrix in solvent ( solvent provides 
30-60 w/w % of the overall system); 30 w/w % ( +/-10%) 
comprises bioceramic particles and 5-10 w/w % (+/-10%) 
comprises hydrogel particles. For example, the system may 
comprise a 30 w/w % PLGA solution in NMP, 30 w/w % HA 
nanopowder and 3-20% w/w % PBAE microparticles. 
EXAMPLES 
Example 1 
In situ forming implants are an attractive choice for 
controlled drug release into a fixed location. Currently, 
rapidly solidifying solvent exchange systems suffer from a 
high initial burst, and sustained release behavior is tied to 
polymer precipitation and degradation rate. The present 
example investigated addition of hydroxyapatite (HA) and 
drug-loaded poly(~-amino ester) (PBAE) microparticles to 
in situ forming poly(lactic-co-glycolic acid) (PLGA)-based 
systems to prolong release and reduce burst. PBAEs were 
synthesized, imbibed with simvastatin ( osteogenic) or clo-
dronate (anti-resorptive), and then ground into micropar-
ticles. Microparticles were mixed with or without HA into a 
PLGA solution, and the mixture was injected into buffer, 
leading to precipitation and creating solid scaffolds with 
embedded HA and PBAE microparticles. Simvastatin 
release was prolonged through 30 days, and burst release 
was reduced from 81 % to 39% when loaded into PBAE 
microparticles. Clodronate burst was reduced from 49% to 
32% after addition of HA filler, but release kinetics were 
unaffected after loading into PBAE microparticles. Scaffold 
dry mass remained unchanged through day 15, with a 
pronounced increase in degradation rate after day 30, while 
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wet scaffolds experienced a mass increase through day 25 
due to swelling. Porosity and pore size changed throughout 
degradation, likely due to a combination of swelling and 
degradation. The system offers improved release kinetics, 
multiple release profiles, and rapid solidification compared 5 
to traditional in situ forming implants. 
Materials 
PBAE Polymer Synthesis 
PBAE macromer was synthesized by reacting diethylene 
glycol diacrylate and isobutylamine at a 1.2:1 diacrylate: 10 
amine molar ratio at 85° C. for 16 hours. Macromer was 
14 
dronate was loaded into separate batches of microparticles 
using an identical pre-loading technique with a 50 mg/mL 
clodronate solution in deionized water. 
Measurement of Drug Loading into PBAE 
Simvastatin loading into PBAE microparticles was mea-
sured by immersing drug-loaded particles in ethanol, vor-
texing, and allowing the particles to swell for 24 hours. The 
mixtures containing ethanol and swollen PBAE micropar-
ticles were then centrifuged, and supernatants were analyzed 
using HPLC to detect simvastatin, as described below. 
Clodronate loading was measured with an identical tech-
nique using 50% ethanol, and was detected by absorbance as 
described below. A mass balance indicated that all drug was 
successfully removed from the particles during 24 hours of 
15 immersion in ethanol for simvastatin or 50% ethanol solu-
stored in an opaque vial under refrigeration until use. To 
create crosslinked hydrogels from macromer, 1 wt/wt % 
DMPA initiator dissolved in 50 wt/wt % ethanol was vor-
texed with macromer. The mixture was then pipetted 
between two glass plates with Teflon spacers, sealed and 
clamped, and then exposed to a UV flood source with an 
intensity of 12 mW /cm2 for 5 minutes to form a crosslinked 
hydrogel slab. These PBAE polymer slabs were washed 
overnight in ethanol to remove unreacted monomer and 20 
initiator, and then stored in a desiccator to remain dry until 
use. 
PBAE Particle Formation and Drug Loading 
tions for clodronate, and subsequent immersions extracted 
no additional drug. Loading efficiency was defined as the 
ratio of the total mass of drug loaded into the particles to the 
initial mass of drug exposed to the particles. 
In addition to loading efficiency, the percentage of drug 
present on the surface of particles was determined by 
washing drug-loaded particles with 5 mL ethanol over a 
filter to remove loosely surface-bound simvastatin or with 5 
mL deionized water to remove loosely surface-bound clo-PBAE microparticles were formed by grinding dry PBAE 
slabs with a mortar and pestle, with HA added during the 
grinding process to coat particles and prevent aggregation. 
HA content was preliminarily tested at 66 w/w % and 75 
w/w % weight ratios, and 75% (50 v/v %) was chosen due 
to ease of particle fabrication. PBAE particles were sieved 
25 dronate. The remainder of drug present in the bulk of the 
microparticles was extracted by immersing particles for 24 
hours in ethanol for simvastatin or 50% ethanol for clodro-
nate. Drug detected in the initial wash was deemed loosely 
bound to the surface of particles, while drug detected after 
to less than 250 µm, and larger particles were re-ground until 30 the 24 hour soak was determined to be imbibed into the bulk 
all material was collected through the sieve. A Zeiss Evo 
MA 10 scanning electron microscope (SEM) (Carl Zeiss, 
Thornwood, N.Y.) at 4 kV accelerating voltage was used to 
visualize particle morphology, and a Quantax energy-dis-
persive x-ray spectroscopy (EDS) detector was used for 35 
elemental analysis. A series of 10 microscope images of HA 
and PBAE particles were analyzed using freely available 
ImageJ software to calculate mean particle size. 
Simvastatin was either loaded into PBAE slabs prior to 
particle formation (pre-loaded) or loaded directly into PBAE 40 
microparticles (post-loaded), and each method was assessed 
for loading efficiency as well as the percentage of drug that 
was weakly bound to particle surface. FIG. 6A graphically 
represents the processing method for creating PBAE 
microparticles, as well as the differences between pre- and 45 
post-loaded particles. Post-loaded particles were prepared 
by dissolving simvastatin in ethanol at a concentration of 
100 mg/mL and pipetting drug solution over particles at a 
ratio of 2 µL per mg of particles. This ratio allowed particles 
to swell without excess solution remaining, and expected 50 
drug loads were calculated under the assumption that all 
drug solution was imbibed by the microparticles. Particles 
were lyophilized overnight, briefly re-ground and sieved to 
break up aggregates, and stored in a vacuum chamber with 
desiccant. Pre-loaded microparticles were prepared by 55 
immersing PBAE slabs in simvastatin solution, allowing the 
hydrogel to swell for 24 hours, and then removing the 
hydrogel and lyophilizing overnight to evaporate ethanol. 
Drug-loaded PBAE slabs were ground with 75 wt% HA into 
particles and stored in a vacuum chamber with desiccant. 60 
Predicted values for drug loading using the pre-loading 
method were obtained by calculating swelling of PBAE in 
solution based on mass increase and assuming drug was 
homogeneously present in swollen hydrogels as well as 
surrounding solution. The density and concentration of the 65 
drug solution was then used to calculate expected drug 
loading based on mass change of the PBAE samples. Clo-
of the particles. 
Formation of Injectable Scaffold System 
PLGA was added to NMP and stirred overnight until fully 
dissolved to create a 20 wt/wt % PLGA solution. Simvas-
tatin-loaded PBAE microparticles pre-loaded using 100 
mg/mL simvastatin were added at 5 wt % and mixed 
homogeneously prior to injection. HA was also mixed 
homogeneously prior to injection to bring the final mixture 
to 30 wt % HA. Clodronate-loaded PBAE microparticles 
pre-loaded with 50 mg/mL clodronate were added using an 
identical technique. Samples without microparticles were 
prepared by freely mixing 1 wt % simvastatin or clodronate 
into 20% PLGA solution to simulate a traditional in situ 
forming PLGA system. FIG. 6B illustrates the differences 
between the proposed system and a traditional injectable 
system. Simvastatin and clodronate were measured as 
described below. 
In Vitro Drug Release 
The scaffold mixture was injected dropwise through a 16 
gauge, blunt-tipped dispensing needle into PBS at 5% 
wt/vol. Upon contacting PBS, surface PLGA immediately 
began to precipitate, forming semi-spherical scaffolds 
approximately 3 mm in diameter that sank to the bottom of 
the vial. Samples were kept in an incubator at 37° C. on a 
plate shaker for the duration of the study. Supernatant was 
collected and replaced at each time point, and these samples 
were preserved at 4° C. until analysis. Clodronate release 
was measured for three loading conditions: freely mixed 
clodronate without HA filler, freely mixed clodronate with 
HA filler, and clodronate pre-loaded into PBAE micropar-
ticles with HA filler. Because PBAE microparticles were 
fabricated with HA as a dispersing agent, drug release from 
loaded particles was not investigated without HA filler. 
Simvastatin release was measured for three loading condi-
tions: freely mixed simvastatin without HA filler, freely 
mixed simvastatin with HA filler, and simvastatin pre-loaded 
into PBAE microparticles with HA filler. 
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Measurement of Drug Concentrations 
Simvastatin was measured on a Hitachi Primaide HPLC 
system equipped with a C18 colunm using a mobile phase 
composed of 70% acetonitrile and 30% water with 0.1 % 
trifluoroacetic acid at a flow rate of 1 mL/min, and peaks 
were observed at 240 nm. Clodronate from collected super-
natants were measured using a Powerwave HT (Biotek; 
Winooski, Vt., USA). In vitro release supernatant was 
pipetted into a UV-grade 96-well plate (Greiner Bio-One, 
Frickenhausen, Germany), and baseline absorbance was 
measured at 240 nm. On its own, clodronate does not exhibit 
a distinct absorption peak, so concentration was measured 
by mixing supernatant with a solution of 1.5 mM copper 
sulfate and 1.5 mM nitric acid at pH 2 to form a clodronate-
copper complex that exhibits absorption at 240 nm. A pilot 
experiment confirmed that HA did not significantly interfere 
with clodronate readings in the working range. 
Characterization of Release Kinetics 
Drug release from polymeric systems is often analyzed 
using an adaptation of the Higuchi model by Peppas et al., 
widely known as the power law, to characterize release 
kinetics (Siepmann J, Peppas NA. Modeling of drug release 
from delivery systems based on hydroxypropyl methylcel-
lulose (HPMC). Advanced Drug Delivery Reviews 2001; 
48: 139-57): 
(1) 
Here, M, is the mass of drug at time t, M is the total mass 
of drug in the system, 
16 
Mass Loss and Degradation 
The injectable scaffold system was prepared as described 
previously, using unloaded microparticles. Non-destructive 
degradation analysis was performed on hydrated scaffolds in 
5 order to observe the mass change of wet samples. Scaffolds 
were injected dropwise into PBS and incubated at 37° C. on 
a shaker for 80 days. Initial injected mass was recorded for 
each scaffold. At intervals, scaffolds were removed from 
PBS, gently blotted dry, and weighed. Destructive analysis 
10 
of dried samples was used to analyze scaffold dry mass 
change. Scaffolds were injected dropwise into PBS and 
incubated at 37° C. on a plate shaker until analysis. At each 
time point, scaffolds were lyophilized for 24 hours, and dry 
weight was measured. Lyophilized scaffolds were also 
scanned using a Scanco MicroCT 40 (Scanco Medical, 
15 Switzerland) at 55 kV and 145 mA with 6 µm voxel size. The 
built in bone trabecular morphometry tool was used to create 
3D reconstructions to visualize microarchitecture and quan-
tify porosity and pore size at various time points during the 
degradation process. 
20 Statistical Analysis 
All data are presented as mean±standard deviation. 
Release data were analyzed in JMP 10 software, using 
one-way analysis of variance (ANOVA) to determine dif-
ferences between release curves followed by Tukey-Kramer 
25 mean comparison tests as necessary. Comparisons between 
individual pairs of samples for loading efficiencies were 
performed using a student's two-tailed t-test. Differences 
were considered significant for p<0.05. 
Results 
30 Drug Loading into PBAE Particles. 
Drug loading into PBAE increased linearly with drug 
solution concentration for simvastatin (FIG. 7A) and clo-
dronate (FIGS. 7B and 7C). Clodronate became insoluble at 
20 mg/mL in 50% ethanol, while the drug remained soluble 
35 through 100 mg/mL in DI water. At 100 mg/mL clodronate, 
however, it was observed that hydrogel would swell to a 
greater degree and fracture upon handling, leading to high 
variability between samples (FIG. 7C), so 50 mg/mL clo-
dronate in DI water was used for future experiments. Sim-
40 vastatin was loaded into gels or particles using a 100 mg/mL 
solution in 100% ethanol. represents Tractional release or drug at time t, k is a constant 
encompassing scaffold and drug properties, and it is the 
release exponent used to characterize drug release. In the 
case of the spherical geometry ( consistent with scaffolds 
formed via dropwise injection), n=0.43 corresponds to pure 
45 
Fickian diffusion, n=0.85 corresponds to pure case II (poly-
mer relaxation-based) transport, and values in between are 
combinations of the two, termed anomalous transport (Siep-
mann J, Peppas NA. Modeling of drug release from delivery 
systems based on hydroxypropyl methylcellulose (HPMC). 
50 
Advanced Drug Delivery Reviews 2001; 48:139-57). Plots 
HA possessed a mean particle diameter of 10 µm, while 
the PBAE particles produced by grinding PBAE hydrogels 
together with HA had a mean diameter of 68 µm. PBAE 
microparticles exhibited a composite structure consisting of 
spherical particles consistent with HA sizes embedded in an 
amorphous material consistent with the hydrogel nature of 
PBAE (FIG. SA). The spherical HA particles exhibited a 
rough, granular surface morphology, compared to the 
smooth PBAE component. EDS elemental mapping showed 
calcium and phosphorous localized to the spherical particles 
of 
versus log t were used to determine n for each drug. The 
power law is applicable when 
M, 
M= < 0.6, 
(FIG. SB). Point analysis of presumed HA and PBAE 
regions indicated higher calcium and phosphorous levels in 
spherical HA particles, and higher carbon and oxygen con-
55 tent in the PBAE region (FIG. SC). When these micropar-
ticles were immersed in a mixture of 20% PLGA solution in 
NMP with 30 wt % HA added to simulate pre-injection 
conditions, they underwent a 47% mass increase due to 
swelling (FIG. SD), with a 28% increase occurring within 5 
60 minutes. 
Efficiency of incorporating simvastatin into post-loaded 
particles ranged from 52% to 77% (FIG. 9B), and efficiency 
ranged from 89% to 96% in pre-loaded particles (FIG. 9D). 
A surface wash indicated that between 69% and 77% of 
65 simvastatin was loosely surface-bound to post-loaded par-
so release data were truncated to below 60% cumulative ticles, with no differences between simvastatin concentra-
release when calculating n. tions (FIG. 9C). Using the pre-loading technique, a signifi-
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cantly lower amount (p<0.05), between 46% and 51 % of 
simvastatin, was loosely surface-bound, again with no con-
centration dependence (FIG. 9A). Pre-loaded clodronate 
yielded particles with 74% to 86% of drug loosely surface-
bound (FIG. 9E). Clodronate loading efficiency ranged from 5 
91 % to 97% at concentrations up to 50 mg/mL, and dropped 
to 59% at 100 mg/mL. 
In Vitro Release 
18 
porous, and the denser regions near the edges of scaffolds 
had become more porous. The dense regions appeared to 
migrate towards one side of the scaffold by day 30, and by 
day 35, scaffolds had significantly decreased in size, leaving 
behind a uniformly porous pellet. After day 35, scaffolds 
were too fragile to handle, and a representative sample of 
residual material collected at day 40 was nonporous. 
MicroCT morphometry revealed an increase in porosity 
from 31 % through day 20 to 4 7% by day 30, followed by a Freely mixed simvastatin was 81% released within 1 day 
and 95% released within 10 days, with no difference 
between scaffolds prepared with or without HA (FIG. lOA). 
In both cases, there was a gradual decrease in release rate as 
fractional release (M/M=) reached 100%. Pre-loaded sim-
vastatin microparticles mixed into the system reduced the 1 
day burst to 39% (p<0.05), followed by sustained release of 
1.3%/day for 30 days. The sustained release from day 1 
through day 30 was roughly linear, with no appreciable 
decrease in rate until completion of drug release. 
10 return to 30% at day 35 (FIG. 13A). Average pore size 
ranged from 40 to 100 µm, except for samples at day 25, 
which had average pore size of 231 µm (FIG. 13B). 
Discussion 
PBAE microparticles were successfully formed by co-
Freely mixed clodronate prepared without HA exhibited a 
49% burst within one day of release, while both freely mixed 
and pre-loaded clodronate prepared with HA produced 32% 
burst (p<0.05) (FIG. lOB). Freely mixed clodronate without 
HA gradually released at a rate of0.6%/day through day 19, 
while clodronate mixed with HA or pre-loaded into 
microparticles released at 1.3%/day through day 19. By day 
20, there was no difference in total clodronate release 
between each curve. All clodronate release curves showed a 
15 grinding PBAE hydrogels with HA, forming individual 
PBAE particles coated with multiple, smaller HA particles. 
Elemental analysis confirmed that the smaller, spherical 
coating consisted of HA, and the underlying particles were 
hydrogel. Simvastatin pre-loaded into PBAE hydrogels 
20 showed both higher loading efficiency and bulk imbibition 
of drug, which are favorable conditions to prolong drug 
release relative to freely mixed drug. Swelling data were 
found to be an accurate predictor of drug loading into gels 
at various concentrations, consistent with previous drug 
25 loading results with hydrogels (Kim S, Bae Y, Okano T. 
distinct increase in release rate to 3%/day at day 20 that 
continued through day 31, after which nearly all drug was 
30 
released. 
To characterize release kinetics, plots of 
Hydrogels: Swelling, Drug Loading, and Release. Pharma-
ceutical Research 1992; 9:283-90). It was determined that 
processing of particles does not appreciably affect simvas-
tatin loading efficiency using the pre-loading technique 
while still providing favorable imbibition ratios of surface to 
bulk drug. A decrease in loading efficiency as well as a 
higher percentage of simvastatin present loosely bound to 
the surface of particles using a post-loading technique may 
be attributable to the free HA powder used to coat the PBAE 
35 particles absorbing a percentage of drug solution, preventing 
its complete penetration into the hydrogel and resulting in a 
majority of drug sequestered outside the hydro gel micropar-
ticles. The high levels of surface drug seen for clodronate vs log t were used to calculate n for pre-loaded simvastatin 
and clodronate through the first day of release. After the first 
day, release rates tended to be linear and were therefore 40 
expressed as a daily release rate. For initial release during 
the burst, simvastatin and clodronate release exhibited 
n=0.47 and n=0.49, respectively. 
Mass Loss and Degradation 
Lyophilized scaffolds exhibited an initial mass loss of 45 
50% in the first hour, followed by an additional gradual 
decrease of 5% over the first day (FIG. llA). Mass fraction 
remained unchanged at approximately 45% for 15 days, 
followed by a linear decrease in mass at a rate of 0.2%/day 
until day 50. Mass fraction did not change significantly after 50 
day 50, ranging from 25% to 29% through day 80. 
Lyophilized samples collected at day 40 and beyond were 
primarily powder that crumbled upon handling. 
Non-destructive mass change of wet scaffolds showed an 
initial 12% decrease in mass over the first day, followed by 55 
a linear increase of 1.4%/day over the next 14 days (FIG. 
llB). At day 15, mass fraction became more variable as 
some samples began to decrease in mass, while others 
swelled through day 30. Linear mass loss was observed from 
day 30 through day 55, when the remaining mass fraction 60 
stabilized at 20% until day 80. 
Qualitative assessment of microCT cutplanes roughly 
bisecting samples revealed a uniformly porous microstruc-
ture through day 10 (FIG. 12). By day 15, denser regions had 
developed in the middle and at the edges of scaffolds. By day 65 
20, large macropores were present in the core of the scaf-
folds. At day 25, scaffold cores appeared more uniformly 
pre-loading may be due to the fact that the PBAE used in 
these experiments swells to a significantly larger degree in 
ethanol than in water (data not shown), allowing less pen-
etration of drug into the bulk of the gels. Additionally, 
clodronate was more favorably loaded into PBAEs in aque-
ous solutions rather than 50% ethanol solutions because its 
solubility was limited. The swelling kinetics of PBAEs in 
the injection mixture (30 wt % HA in 20% PLGA solution) 
suggest that particles swell appreciably due to NMP expo-
sure prior to injection, but the magnitude of swelling is 
negligible compared to the amount observed in pure NMP 
(47% at equilibrium vs. 470% in pure NMP). This difference 
is due to the presence of PLGA, which dissolves readily in 
NMP (Lambert W J, Peck K D. Development of an in situ 
forming biodegradable poly-lactide-coglycolide system for 
the controlled release of proteins. Journal of Controlled 
Release 1995; 33:189-95) and prevents hydrogels from fully 
swelling as they would in pure NMP. Additionally, the 
particles may be immersed in PLGA solution for only a 
matter of minutes before injection, so realistically, particles 
may swell by only 23% if the system is injected 5 minutes 
after addition of microparticles to the PLGA solution. 
Simvastatin release was strongly affected by its loading 
state. A comparison of release kinetics between injectable 
systems loaded with freely mixed simvastatin and simvas-
tatin-loaded PBAE microparticles indicated that burst 
release can be significantly reduced and duration of release 
can be significantly extended by loading simvastatin into 
PBAE microparticles. Because simvastatin is soluble in 
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NMP, freely mixed drug presumably was dissolved in NMP 
and the majority of it exited into the aqueous phase during 
the solvent exchange process, resulting in a large burst 
release. The residual 20% of simvastatin was released in a 
sustained manner over the next 10 days, similar to previous 
work on such systems using freely mixed drug (Tang Y, 
Singh J. Controlled delivery of aspirin: effect of aspirin on 
polymer degradation and in vitro release from PLGA based 
phase sensitive systems. International Journal of Pharma-
ceutics 2008; 357:119-25; Bakhshi R, Vasheghani-Farahani 
E, Mobedi H, Jamshidi A, Khakpour M. The effect of 
additives on naltrexone hydrochloride release and solvent 
removal rate from an injectable in situ forming PLGA 
implant. Polymers for Advanced Technologies 2006; 
17:354-9). PBAE microparticles experience some swelling 
in the NMP-PLGA solution during the mixing stage prior to 
injection, but burst is attenuated for pre-loaded PBAE 
microparticles. The 39% burst release through day 1 using 
pre-loaded particles may be attributable to loosely surface-
bound simvastatin that was likely dissolved by NMP and 
released during solvent exchange, similarly to freely-mixed 
simvastatin. Because simvastatin was loaded into PBAE 
with high efficiency, the release kinetics are likely a com-
bination of the swelling, degradation, and diffusion of drug 
through the PBAE material as well as the PLGA phase. 
Clodronate release appeared to be unaffected by loading 
state of the drug in PBAE microparticles, but it was instead 
dependent on the presence of HA in the injection mixture. 
This can be attributed to the formation of a complex between 
the bisphosphonate drug and hydroxyapatite, specifically 
between the two phosphonate groups of clodronate and the 
divalent calcium cations present in HA crystals (Nancollas G 
20 
delivery depot may have advantages over gradually precipi-
tating systems with persistent gel or liquid cores for days or 
weeks after injection due to NMP retention (Bakhshi R, 
Vasheghani-Farahani F, Mobedi H, Jamshidi A, Khakpour 
5 M. The effect of additives on naltrexone hydrochloride 
release and solvent removal rate from an injectable in situ 
forming PLGA implant. Polymers for Advanced Technolo-
gies 2006; 17:354-9). Specifically, this has implications for 
intraosseous injection, where the system can completely 
10 precipitate within days while continuing to release drug over 
a period of weeks to months. In systems with freely sus-
pended or dissolved drug, precipitation rate strongly influ-
ences burst release (Graham PD, Brodbeck K J, McHughA 
J. Phase inversion dynamics of PLGA solutions related to 
15 drug delivery. Journal of Controlled Release 1999; 58:233-
45; Yewey G L, Duysen E G, Cox S M, Dunn R L. Delivery 
of proteins from a controlled release injectable implant. 
Pharmaceutical biotechnology 1997; 10:93-117), and the 
addition of drug-loaded PBAE microparticles can allow for 
20 prolonged release and decreased burst without prolonging 
precipitation of the system. The rapid precipitation may also 
allow filler particles, such as hydroxyapatite, to provide 
mechanical support in future iterations of the system. After 
the initial burst, pre-loaded simvastatin exhibited prolonged 
25 delivery over the entire 30 day period. The lack of change in 
simvastatin release kinetics upon addition of 30 wt % HA 
was expected, because HA should not appreciably interact 
with statins, which lack the phosphonate groups that provide 
binding sites for the calcium in HA. The successful dem-
30 onstration of sustained release of both hydrophilic and 
hydrophobic small molecule drugs with reduced burst from 
this system shows promise for new applications of in situ 
forming PLGA systems where rapid precipitation is H, Tang R, Phipps R J, Henneman Z, Guide S, Wu W, et al. 
Novel insights into actions of bisphosphonates on bone: 
differences in interactions with hydroxyapatite. Bone 2006; 35 
38:617-27). Freely mixed clodronate without HA filler was 
49% released within 1 day, compared to 32% for both 
compositions with HA. Because clodronate is insoluble in 
NMP, this initial burst is likely due to free clodronate 
suspended in the PLGA solution being dissolved by water 
during solvent exchange. The increase in release rate 
observed around day 20 corresponded to the maximum 
swelling state of scaffolds, indicating that scaffolds had 
begun to appreciably degrade and more water could enter 
the system to promote more rapid clodronate dissolution. 
Samples prepared with HA had a lower burst and higher 
release rate between days 1 and 20 due to the clodronate 
being initially retained in the system by complexation, after 
which the drug was released diffusively from the solidified 
system. Clodronate release kinetics are consistent with the 50 
classic three-stage release profiles observed in rapidly-pre-
cipitating systems, in which an initial burst is followed by 
slow diffusion, and then a more rapid swelling- or degrada-
tion-mediated release occurs (Fredenberg S, Wahlgren M, 
Reslow M, Axelsson A. The mechanisms of drug release in 55 
polylactic-co-glycolic acid)-based drug delivery sys-
tems-A review. International Journal of Pharmaceutics 
2011; 415:34-52). Interestingly, the slow diffusion stage was 
accelerated by the addition of HA, likely because the larger 
amount of drug retained in the scaffold provided a higher 60 
concentration gradient to drive diffusion. 
required. 
By fitting the power law to initial drug release, the release 
exponent n can be used to classify the mechanism of drug 
release from the system. For simvastatin, n of0.47 indicates 
primarily Fickian diffusion based on the standard n values 
for a spherical scaffold ofn=0.43 for pure Fickian diffusion 
40 and n=0.85 for pure Case II transport. The slightly higher 
release exponent compared to the pure Fickian value can be 
attributed to several factors, including the swelling of the 
PBAE hydrogel microparticles and minor swelling of the 
surrounding PLGA matrix. Similarly, n of 0.49 for clodro-
45 nate corresponds to primarily Fickian diffusion as well. Both 
clodronate and simvastatin are therefore released via diffu-
sive mechanisms prior to their sustained release, which 
follows a more linear trend. This data supports the idea that 
the burst was composed of a fraction of the loaded drug 
dissolved or suspended in NMP, and the rapid solvent 
exchange was likely responsible for the initial release. The 
sustained release was likely a combination of diffusion, 
erosion, and swelling-based mechanisms, and the superpo-
sition of these mechanisms produces release curves that are 
most simply expressed in daily release rates. Because sim-
vastatin is almost insoluble in water but highly soluble in 
NMP, the larger burst compared to clodronate is unsurpris-
ing, as dissolved simvastatin may be transported out of the 
scaffold during the solvent exchange phase. Future iterations 
of the system may be able to further reduce burst by 
reducing access of drug to the NMP phase to limit the initial 
diffusive component of the system. The rapid precipitation implied by the initial burst of 
clodronate and simvastatin as well as the early mass loss is 
indicative of rapid NMP exchange, which demonstrates the 
potential of the system for rapid solidification. Fast precipi- 65 
tation is favorable for quick delivery of NMP for an initial 
osteogenic stimulus, and rapid formation of a solid drug 
PLGA is a bulk-eroding material that degrades via hydro-
lysis of ester bonds, resulting in a progressive decrease in 
molecular weight until monomeric or oligomeric species of 
sufficiently low molecular weight are generated and cleared 
when molecular weight drops to approximately 1.5 kDa 
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(von Burkersroda F, Schedl L, GopferichA. Why degradable 
polymers undergo surface erosion or bulk erosion. Bioma-
terials 2002; 23:4221-31; Kenley RA, Lee M 0, Mahoney 
TR, Sanders L M. Poly(lactide-co-glycolide) decomposition 
kinetics in vivo and in vitro. Macromolecules 1987; 5 
20:2398-403). The in situ forming scaffold has the additional 
property of a rapid precipitation event upon injection, and 
due to the high aqueous miscibility of NMP, a rapid initial 
dry mass loss was observed within the first hour following 
injection as NMP entered the aqueous phase and the highly 10 
hydrophobic PLGA precipitated. By 24 hours, 46% dry mass 
remained, corresponding to the loss of the majority of the 
NMP content that composed 54 wt % of the system. The 
subsequent lack of dry mass change suggests that hydrolytic 
degradation was unable to produce small enough molecular 15 
weight species to be cleared into the surrounding aqueous 
environment until day 15. After day 15, the linear decrease 
in dry mass corresponded to clearance of degradation 
byproducts until all PLGA was removed from the system. 
The remaining 29% dry mass can be attributed to remaining 20 
HA content that composed 30% of the original mass. For wet 
scaffolds, the initial 12% decrease in wet mass throughout 
the first day of degradation supports the replacement of 
NMP with water due to precipitation of PLGA. The 20% 
increase in wet mass over the following 14 days indicates 25 
swelling of the PLGA matrix. Following this brief swelling, 
individual sample behavior diverged as swelling reached a 
maximum between 110-120% between days 20-30. The 
linear decrease in mass was delayed compared to dry 
samples because the small losses in polymer degradation 30 
byproducts were offset by increased water content as the 
system swelled. The lack of mass change beyond day 55 was 
consistent with the complete clearance of PLGA observed in 
dry mass studies, and the lower mass fraction remaining 
(20% compared to 29%) was likely due to repeated handling 35 
of samples during nondestructive measurements resulting in 
small amounts of HA being resuspended and removed with 
supernatant at each time point. 
Based on microCT images, it was evident that scaffold 
microarchitecture underwent dramatic changes throughout 40 
the degradation process. The first indicator of change was 
the development of denser regions in the core and near the 
edges of scaffold by day 15, which may be attributable to the 
cessation of NMP release and the hydrophobicity of PLGA 
causing solid regions to condense together. At day 20, the 45 
highest pore size was observed as large, closed macropores. 
This phenomenon corresponds to the scaffolds at their 
maximum swelling state based on wet mass, and was 
accompanied by further densification of the core and edge 
regions. At day 25, the core remained dense, but macropores 50 
were no longer evident, and the edges of scaffolds were less 
dense and more porous, which is consistent with reports of 
PLGA of this molecular weight beginning to lose mass to 
clearance after 3 weeks (Kenley RA, Lee M 0, Mahoney T 
R, Sanders L M. Poly(lactide-co-glycolide) decomposition 55 
kinetics in vivo and in vitro. Macromolecules 1987; 
20:2398-403). At day 30, it is possible that enough polymer 
had been lost to allow mobility of HA content through the 
PLGA, which settled at the bottom of scaffolds during 
incubation. By day 35, scaffold density and pore distribution 60 
appeared more uniform, and scaffolds were noticeably 
smaller in size due to further degradation of the highly 
porous regions seen at day 30. 
In situ forming PLGA systems have been popularized due 
to their ease of use and unique ability to solidify at the point 65 
of injection, forming a drug delivery depot in the tissue of 
interest. However, because drug release from these systems 
22 
is highly dependent on solvent exchange and polymer chem-
istry (Graham P D, Brodbeck K J, McHugh A J. Phase 
inversion dynamics of PLGA solutions related to drug 
delivery. Journal of Controlled Release 1999; 58:233-45), 
release of multiple agents with unique release profiles is 
challenging. Additionally, low molecular weight drugs tend 
to exit during the solvent exchange, resulting in high initial 
burst (Parent M, Nouvel C, Koerber M, Sapin A, Maincent 
P, Boudier A. PLGA in situ implants formed by phase 
inversion: Critical physicochemical parameters to modulate 
drug release. Journal of Controlled Release 2013; 172:292-
304). Multiple drug release platforms for small molecule 
drugs, therefore, tend to be pre-formed scaffolds or inject-
able suspensions of micro- or nanoparticles (Biondi M, 
Ungaro F, Quaglia F, Netti PA. Controlled drug delivery in 
tissue engineering. Advanced Drug Delivery Reviews 2008; 
60:229-42; Zhang L, Radovic-Moreno AF, Alexis F, Gu F 
X, Basta PA, Bagalkot V, et al. Co-Delivery of Hydrophobic 
and Hydrophilic Drugs from Nanoparticle-Aptamer Biocon-
jugates. ChemMedChem 2007; 2:1268-71; Sokolsky-Pap-
kov M, Agashi K, Olaye A, Shakesheff K, Domb A J. 
Polymer carriers for drug delivery in tissue engineering. 
Advanced Drug Delivery Reviews 2007; 59:187-206; Zhou 
T, Lewis H, Foster RE, Schwendeman S P. Development of 
a multiple-drug delivery implant for intraocular manage-
ment of proliferative vitreoretinopathy. Journal of Con-
trolled Release 1998; 55:281-95). The addition of PBAE 
microparticles to the in situ forming PLGA system combines 
the ease of use of injectable systems, the controlled release 
of microparticle systems, and the spatial control of solid 
scaffolds. Even in a rapidly-solidifying system, PBAE 
microparticles are capable of prolonging release of both 
hydrophilic and hydrophobic drugs over a 30 day period 
with significantly less burst than traditional injectable PLGA 
systems using freely mixed drug. 
Conclusions 
An in situ hardening, PLGA-based system offers a unique 
drug delivery platform due to its injectability and space-
filling properties, and the addition of drug-loaded micropar-
ticles introduces the possibility for tunable release profiles 
for multiple pharmaceutical agents. In addition to the poten-
tial for multiple release profiles, the addition of drug-loaded 
PBAE microparticles enables the sustained release ofwater-
soluble, small molecule drugs, such as clodronate, as well as 
lipophilic drugs, such as simvastatin, independent of PLGA 
precipitation. The biodegradability of the system makes this 
a favorable candidate for applications where a secondary 
surgery to remove the depleted scaffold is undesirable or 
impossible. Release kinetics can be multiphasic simply by 
loading drug freely into the PLGA solution for burst release, 
or into PBAE microparticles for sustained release with 
reduced burst. This injectable scaffold provides the simplic-
ity of a targeted injection with the utility of an implantable 
drug delivery scaffold without compromising desirable 
release kinetics. 
Example 2 
In situ forming scaffolds containing hydroxyapatite 
micro- and nanoparticles were characterized to determine 
their mechanical properties, injectability, and microarchitec-
ture. Scaffolds were prepared with various concentrations of 
hydroxyapatite, as well as poly(~-amino ester) micropar-
ticles that facilitate drug delivery. Strength was increased 
three-fold, from 2 to 6 MPa, while compressive modulus 
was improved 6-fold, from 24 to 141 MPa, via the addition 
of 30% nano-hydroxyapatite, which provided greater ben-
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efits at equivalent concentrations compared to micro-hy-
droxyapatite. Scaffolds retained a uniformly porous micro-
architecture, and hydroxyapatite particles were distributed 
evenly throughout the PLGA phase. Injectability, deter-
mined by the force required to inject 0.5 mL of material 5 
within 60 seconds, remained clinically acceptable at <50 N 
at 30% w/w hydroxyapatite and up to 10% w/w PBAE 
microparticles. Ex vivo injections into intact porcine femo-
ral heads increased compressive modulus oftrabecular bone 
from 81 to 180 MPa and strength from 3.5 to 5.9 MPa. This 10 
injectable scaffold offers mechanical reinforcement coupled 
with previously demonstrated drug delivery potential in a 
single injection for bone-weakening conditions, such as 
24 
wise indicated. PBS was replaced daily to prevent accumu-
lation of NMP or low molecular weight species that were 
cleared from the scaffolds. 
Mechanical Properties of Cylindrical Scaffolds 
All compression tests were performed using a Bose ELF 
3300 mechanical testing instrument. Modulus was calcu-
lated as the slope of the initial linear region of the stress-
strain curve (approximately the first 5-10% strain). Yield 
stress was determined as the stress at which the stress-strain 
curve became nonlinear. To first identify any strain rate-
dependence of mechanical properties, scaffolds prepared 
with increasing MHA content were tested in unconstrained 
compression to 50% strain at displacement rates of 0.006, 
0.06, and 0.6 mm/s (strain rates of 0.001, 0.01, and 0.01 s- 1 , osteonecrosis or osteoporosis. 
Synthesis of PBAE Microparticles 
PBAE hydrogel slabs were synthesized as described pre-
viously (Anderson D G, Tweedie CA, Hossain N, Navarro 
15 respectively). The contribution of PBAE microparticles to 
mechanical properties was quantified by increasing PBAE 
content from 1 % to 15% w/w in scaffolds prepared with 30% 
NHA. S M, Brey D M, Van Vliet K J, Langer R, Burdick J A. A 
Combinatorial Library of Photocrosslinkable and Degrad-
able Materials. Advanced Materials 2006; 18(19):2614- 20 
2618; Hawkins AM, Milbrandt TA, Puleo DA, Hilt J Z. 
Synthesis and analysis of degradation, mechanical and tox-
icity properties of poly(~-amino ester) degradable hydro-
gels. Acta Biomaterialia 2011; 7(5):1956-1964). Briefly, 
macromer was created by reacting diethylene glycol diacry- 25 
late with isobutylamine at 85° C. for 16 hours at a 1.2: 1 
molar ratio. This macromer was then photopolymerized 
between two glass plates with 1 % w/w DMPA initiator and 
To determine the effects ofNHA versus MHA on scaffold 
properties, a comparison of mechanical properties for scaf-
folds containing different amounts of MHA and NHA was 
performed at a displacement rate of 1 mm/min (0.0167 
mm/s, or a strain rate of0.0028 s- 1) to 50% strain. Total HA 
content ranged from O to 50% in intervals of 10%. Scaffolds 
were prepared with either pure MHA, pure NHA, or differ-
ent ratios of the two. 
Injectability 
To quantify injectability, scaffold mixtures contmmng 
30% w/w NHAand 5, 10, or 15% w/w PBAE microparticles 
were loaded into a 3 mL syringe affixed with a 1.5 inch, 16 
gauge needle. The loaded syringe was suspended by its 
flanges in a 15 mL centrifuge tube to collect the injected 
mixture, with the end of the tube in contact with the load cell 
and the plunger of the syringe in contact with the axial 
a 1: 1 weight ratio of macromer to microparticulate hydroxy-
apatite (MHA) (Sigma-Aldrich, St. Louis, Mo., USA) to 30 
form a PBAE hydrogel slab. PBAE hydrogels were previ-
ously loaded with drug for use as delivery vehicles, but were 
left unloaded for these experiments. Microparticles were 
formed by grinding PBAE slabs and sieving until all col-
lected particles were 250 µm or less in size. 35 mover. The plunger was subjected to a series of sustained 
loads to simulate injection force, and the resulting displace-
ment of the plunger was recorded. Injectability was quan-
tified by plotting the time to inject 0.5 mL as a function of 
NHA Synthesis 
Nanoparticulate HA (NHA; nGimat, Lexington, Ky., 
USA) was produced at nGimat LLC's facility in Lexington, 
Ky., using a solution combustion process called NanoSpray 
CombustionsM_ This scalable process is capable of produc- 40 
ing synthetic bone minerals, such as HA, tricalcium phos-
phate (TCP), and amorphous calcium phosphate (ACP), 
using cost-effective precursor materials. To produce NHA, a 
calcium carboxylate precursor and an alkyl phosphate pre-
cursor of appropriate proportions were dissolved in an 45 
organic solvent system, the solution was converted to an 
ultrafine spray (referred to as a NanoSpray) using a device 
called a Nanomiser®, and the spray was combusted under a 
controlled atmosphere. The average particle size for the 
NHA was <200 nm, as estimated by BET. X-ray diffraction 50 
confirmed the presence of the HA phase (Ca5 (OH)(PO4 ) 3 ), 
and X-ray fluorescence spectroscopy showed that the Ca:P 
ratio was close to 5:3. 
Formation of Cylindrical Scaffolds 
the injection force. Rational limits of 60 second injection 
time and 50 N injection force were set as the limits of 
injectability based on consultation with an orthopedic sur-
geon. 
Microarchitecture 
Effects of HA on microarchitecture were analyzed by 
preparing scaffolds with increasing NHA and MHA content, 
as well as a variety of NHA/MHA mixtures totaling 30% 
HA, lyophilizing these scaffolds after they had solidified in 
PBS for 3 days, and then scanning them with a SCANCO 
MicroCT 40 (SCANCO Medical AG, Switzerland) at 55 kV 
and 145 mA and 6 µm voxel size. Microarchitecture was 
quantified by porosity and material density. Scanning elec-
tron microscopy (SEM) was used to visualize micro- and 
nanoarchitecture of scaffolds containing 30% w/w NHA. 
Samples were freeze-fractured, coated with gold-palladium 
alloy, and imaged with a Hitachi S-4300 scmming electron 
microscope at 3 kV accelerating voltage. 
Ex Vivo Scaffold Injections 
Humeral heads were harvested from 10 week old male 
piglets euthanized in a separate study, and were kept frozen 
until use, without chemical fixation or removal of marrow. 
Using a 16-gauge, 2.5-inch bone biopsy needle inserted 
through the growth plate into the proximal humeral epiphy-
sis, two humeral heads each received 3 mL ex vivo injec-
tions of30% NHA/5% PBAE scaffolds. Two humeral heads 
PLGA (50:50 L:G, acid terminated, inherent viscosity 55 
0.55-0.75 dL/g) was obtained from DURECT, Inc. (Bir-
mingham, Ala., USA). All experiments used a polymer 
solution of 30% w/w PLGA in NMP (Sigma-Aldrich, St. 
Louis, Mo., USA). PBAE microparticles and MHA or NHA 
were mixed homogeneously into the polymer solution using 60 
a spatula. The scaffold mixture was loaded into a syringe and 
injected through a 16 gauge needle into a cylindrical agarose 
mold, where the system was allowed to solidify in phos-
phate-buffered saline (PBS). Scaffolds contained different 
concentrations of MHA or NHA, ranging from 0% to 50% 
w/w. All scaffolds contained 5% w/w PBAE microparticles 
65 were used as untreated controls. All humeral heads were 
to mimic prior drug release study conditions, unless other-
scanned using microCT prior to injection, immersed in PBS 
for 5 days to allow scaffolds to fully solidify, and then 
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scanned again to quantify scaffold infiltration. After 5 days 
in PBS, a 3 mm diameter cylindrical punch was used to 
remove tissue samples in the mediolateral direction, with the 
punch approaching through the articular cartilage and pen-
etrating through the growth plate, for a total of 7 samples 5 
each for treatment and control groups. These cylindrical 
samples were trimmed to 6 mm in length, using only 
trabecular bone tissue between the growth plate and the 
articular cartilage. All samples were stored in PBS and tested 
the same day in unconstrained compression at a rate of 1 10 
mm/min. 
and the highest yield stress occurring at 1 % PBAE. Increas-
ing PBAE content from 10 to 15% led to a significant 
decrease in modulus from 120 to 84 MPa (p<0.05). Average 
yield stress of 15% PBAE scaffolds was 3.6 MPa, signifi-
cantly lower than 1 % PBAE scaffolds (p<0.05), which had 
an average yield stress of 4.9 MPa. Samples became more 
viscous and difficult to inject into molds as PBAE content 
was increased. Beyond 15% PBAE, the mixture could still 
be injected, but the scaffold began precipitating before it 
could flow and fill the cylindrical mold, resulting in incon-
sistent morphology and unreliable mechanical properties. 
Results 
Strain Rate and MHA Content 
Scaffolds prepared with different MHA contents were 
compressed at strain rates spanning three orders of magni-
tude. At strain rates of 0.001, 0.01, and 0.1 s- 1 (correspond-
ing to displacement rates of 0.006, 0.06, and 0.6 mm/s), 
modulus increased with MHA content (FIG. lA). The high-
est modulus increased from 64 to 82 to 96 MPa for each 
respective strain rate, and overall, moduli ranged from 9 to 
96 MPa. The lowest recorded modulus for any scaffold 
containing HA was 29 MPa (10% MHA, 0.001 s- 1), while 
scaffolds without any HA ranged from 9 to 30 MPa, increas-
ing with strain rate. At 0.001 s-1, significant increases in 
modulus occurred between 0-10% (p<0.01) and 30-50% 
MHA (p<0.01 ). At 0.01 s- 1 , significant increases occurred 
between 0-20% (p<0.05) and 20-50% MHA (p<0.0001). At 
the highest strain rate of 0.1 s- 1 , modulus increased between 
0-10% (p<0.01), 10-30% (p<0.001), and 30-40% MHA 
(p<0.001). For equivalent scaffold formulations, average 
modulus increased with increasing strain rate in every case, 
and this trend was significant at 40% MHA between 0.01 
and 0.1 s-1 (p<0.0001) and at 50% w/w MHA between 
0.001 and 0.01 s-1 (p<0.05). 
Yield stress followed a similar trend to modulus, however 
the differences between scaffold formulations and between 
strain rates were less pronounced (FIG. lB). Yield stresses 
ranged from 1.1 to 7 MPa, and the highest yield stresses at 
the three strain rates of0.001, 0.01, and 0.1 s- 1 were 4.4, 5, 
and 7 MPa, respectively. Addition of 10% MHA to scaffolds 
led to a threefold increase in yield stress at a strain rate of 
0.001 s- 1 (from 1.1 to 3.3 MPa) and a twofold increase in 
yield stress at 0.01 s- 1 (from 2 to 4.2 MPa), while 10% MHA 
scaffolds experienced only a 13% increase (from 4.5 to 5.1 
MPa) at a strain rate of 0.1 s-1. At 0.001 s-1, significant 
increases in yield stress occurred between 0-10% 
(p<0.0001) and 40-50% MHA (p<0.01). At 0.01 s-1, yield 
stress significantly increased at 0-10% (p<0.0001) and 
10-30% MHA (p<0.01 ). At the highest strain rate of 0.1 s- 1 , 
yield stress increased from 0-20% (p<0.05) and 20-50% 
MHA (p<0.05). Similar to modulus, average yield stress for 
equivalent scaffold formulations increased at every strain 
rate. Increasing strain rate from 0.001 to 0.01 s- 1 led to an 
increase in yield stress for 20% (p<0.001), 30% (p<0.01), 
and 40% MHA scaffolds (p<0.001 ). Further increasing strain 
rate from 0.01 to 0.1 s resulted in significantly increased 
yield stress for 0% (p<0.0001), 30% (p<0.01), 40% 
(p<0.01), and 50% MHA scaffolds (p<0.0001). 
PBAE Content 
Scaffolds prepared with 30 w/w % NHA and different 
PBAE microparticle contents were compressed at 1 mm/min 
(0.0028 s- 1). PBAE microparticle content did not signifi-
cantly affect 30% NHA scaffold mechanical properties for 
PBAE content ranging from 1 to 10 w/w %. Moduli ranging 
from 96-120 MPa (FIG. 14A) and yield stresses from 4.3-4.9 
MPa (FIG. 14B) were recorded in these PBAE content 
ranges, with the highest modulus occurring at 10% PBAE 
Ratio of MHA to NHA 
Scaffolds prepared with different amounts of MHA and 
NHA were compressed at 1 mm/min (0.0028 s- 1). All 
15 scaffolds generally increased in modulus up to 30% w/w 
total HA content (FIG. 15A). In scaffolds prepared with only 
MHA, a linear increase in modulus from 33 to 68 MPa was 
observed from 10% through 30% MHA, although no sig-
nificant difference was observed between groups. Modulus 
20 was significantly different between 10% and 50% MHA 
scaffolds (p<0.05). Scaffolds prepared with only NHA 
exhibited a large and significant increase in modulus, from 
53 to 141 MPa, between 20% and 30% NHA (p<0.0001). 
Scaffolds prepared with equal amounts of NHA and MHA 
25 possessed moduli similar to 30% NHA scaffolds, with 15:15, 
20:20, and 25:25 NHA:MHA scaffolds all exhibiting moduli 
between 128 and 151 MPa. Other scaffolds with similarly 
high moduli included mixed NHA and MHA scaffolds with 
total HA concentrations of 50% (10:40, 20:30, and 30:20 
30 NHA:MHA). Notably, 20: 10 scaffolds exhibited signifi-
cantly lower modulus than 15:15 and 30:0 NHA:MHA 
scaffolds (p<0.0001). Scaffolds with 40% and 50% total had 
the highest modulus at a 1: 1 NHA:MHA ratio, which 
decreased when the NHA:MHA ratio was changed in either 
35 direction. 
Yield stress followed trends similar to modulus, however 
the magnitude of these differences was lower (FIG. 3B). For 
example, out of all scaffolds prepared with 30% total HA, 
only 30:0 and 10:20 NHA:MHA samples were significantly 
40 different (p<0.01). Scaffolds made with 40% pure MHA or 
40% pure NHA had significantly lower yield stresses than 
scaffolds prepared with a mixture of NHA and MHA 
(p<0.01). At 50% total HA, scaffolds with 30% or higher 
NHA content possessed lower yield stresses than scaffolds 
45 composed of 25:25, 20:30, or 10:40 NHA:MHA (p<0.01). 
Injectability 
Injectable scaffold mixtures containing 5, 10, or 15 w/w 
% PBAE microparticle content were injected through a 16 
gauge, 1.5 inch needle with a series of increasing injection 
50 forces. For each injection, the displacement of the plunger 
initially increased rapidly due to compression of the rubber 
plunger, the scaffold mixture, and any air bubbles, before 
reaching a period oflinear displacement where flow rate was 
constant, followed by a relaxation period as force was 
55 removed (FIG. 16A). The linear portion of the displacement 
curve was used to calculate displacement rate of the syringe 
plunger, and the internal diameter of the syringe barrel was 
used to calculate volumetric flow rate. The time required to 
inject 0.5 mL of each mixture increased with increasing 
60 PBAE content, and it decreased with increasing injection 
force (FIG. 16B). Scaffolds were considered injectable if a 
0.5 mL injection could be performed in 60 seconds or less, 
which is indicated by the horizontal dashed line in FIG. 16B. 
The 5% PBAE scaffolds were injectable for injection forces 
65 greater than 16 N, 10% PBAE scaffolds became injectable 
at 40 N, and 15% PBAE scaffolds became injectable at 75 
N. The vertical dotted line at 50 Nin FIG. 16B indicates the 
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limit for a reasonable injection force, beyond which sus-
tained forces may be uncomfortable or cause fatigue for the 
surgeon performing the procedure. For each scaffold com-
position, a logarithmic transformation of both injection force 
and injection time resulted in the best fit. 
Microarchitecture 
Visualizing the microarchitecture of scaffolds prepared 
with 30% w/w NHA and 5% w/w PBAE microparticles 
revealed two distinct levels of porosity, with NHA and 
PBAE particles trapped within the solid PLGA matrix. 
Macroscopic pores on the order of 100 µm in diameter were 
scattered throughout the scaffold (FIG. 17 A), and the solid 
PLGA matrix was primarily composed of a microporous, 
honeycomb-like structure with pore sizes on the order of 10 
µm (FIG. 17B). Elongated pores were observed at the 
scaffold surface (FIG. 17C). HA nanoparticles, with spheri-
cal morphology and diameters on the order of 50 nm, were 
present in the PLGA walls of the micropores (FIG. 17D). 
These particles were densely packed in 30% w/w NHA 
scaffolds. 
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for injected bone, with a yield stress of 5.9 MPa for injected 
samples compared to 3.5 MPa for controls (p<0.01). 
Discussion 
The general effects of HA additives on in situ forming 
5 PLGA scaffolds were consistent with existing research on 
preformed, implantable scaffolds (Huang Y X, Ren J, Chen 
C, Ren T B, Zhou X Y. Preparation and Properties of 
Poly(lactide-co-glycolide) (PLGA )IN ano-Hydroxyapatite 
(NHA) Scaffolds by Thermally Induced Phase Separation 
10 and Rabbit MSCs Culture on Scaffolds. Journal of Bioma-
terials Applications 2008; 22(5):409-432; Wei G, Ma P X. 
Structure and properties of nano-hydroxyapatite/polymer 
composite scaffolds for bone tissue engineering. Biomate-
rials 2004; 25(19):4749-4757; Verheyen CC PM, De Wijn 
15 J R, Van Blitterswijk C A, De Groot K. Evaluation of 
hydroxylapatite/poly(l-lactide) composites: Mechanical 
behavior. Journal of Biomedical Materials Research 1992; 
26(10):1277-1296; Guan L, Davies J E. Preparation and 
characterization of a highly macroporous biodegradable 
20 composite tissue engineering scaffold. Journal of Biomedi-
cal Materials Research Part A 2004; 71A(3):480-487), with 
HA additives providing mechanical reinforcement, as evi-
denced by both compressive modulus and yield stress. As 
HA content was increased beyond a certain point (generally 
MicroCT analysis allowed for quantification of micro-
architectural parameters such as porosity and material den-
sity. Porosity generally decreased with increasing total HA 
content, and this trend was most pronounced in samples 
prepared with only MHA, which possessed porosities rang-
ing from 2.4 to 48.1 %, while samples prepared with only 
NHA had a porosity range of 13 to 22.5% (FIG. 18A). 
MHA-only samples experienced a significant decrease in 
porosity from 10-20% (p<0.001) and 30-40% (p<0.05), and 30 
NHA-only samples had a significant decrease in porosity 
from 10-30% (p<0.05). Samples with 30% total HA pre-
pared with different mixtures of MHA and NHA did not 
exhibit significantly different porosity from each other. At 
equivalent weight percentages, samples prepared with pure 35 
NHA had significantly lower porosity than those prepared 
with MHA at 10% (p<0.0001), 20% (p<0.001), and 30% 
(p<0.05), while porosity between the two groups was not 
different at 40% and 50% w/w. 
25 around 30% w/w, depending on the specific MHA and NHA 
content), mechanical properties either plateaued, in the case 
of MHA, or decreased, in the case of NHA. This effect can 
be attributed to the total surface area of HA relative to the 
volume of PLGA, which results in maximal scaffold 
mechanical properties when sufficient PLGA is present to 
bind HA together tightly without excess HA or PLGA. SEM 
images of the 30% NHA scaffolds showed dense packing of 
NHA nanoparticles embedded in the PLGA phase, which 
may explain why further increasing NHA content was not 
beneficial since particles were already in close proximity at 
this loading. MHA scaffolds were mechanically inferior to 
NHA at equivalent concentrations, likely due to the lower 
surface area to volume ratio of MHA, which allowed fewer 
PLGA:HA and HA:HA interfaces to form, and thus led to a 
Material density increased with total HA content, and 
scaffolds prepared with NHA experienced a larger increase 
in density at each 10% increment of HA content (FIG. 18B). 
MHA scaffolds exhibited significantly higher density than 
NHA scaffolds at 10% (p<0.0001) and 20% (p<0.01), but 
due to the smaller rate of increase, they exhibited lower 
density than NHA scaffolds at 30%, 40%, and 50% w/w 
(p<0.0001). The 30% HA scaffolds prepared with a mixture 
of NHA and MHA had lower density at 10:20 NHA:MHA 
formulations than scaffolds prepared with 15: 15 and 20: 10 
NHA:MHA (p<0.0001). 
Ex Vivo Scaffold Injections 
During the injection of scaffolds into the humeral heads, 
fluid was observed leaking out of bone near the growth plate, 
indicating that the scaffold was displacing marrow and 
filling the intertrabecular space. After the 3 mL injection into 
two humeral heads, there was an average reduction in free 
volume of 2.8 mL, corresponding to a 58% filling of the 
intertrabecular volume (data not shown). A comparison of 
cutplanes from a 3D reconstruction of the humeral heads 
showed scaffold material distributed throughout the bone 
volume, with small (sub-millimeter) regions of that were 
unfilled. During removal of the cylindrical cores from 
injected bones, it was observed that scaffold material was 
constrained by the articular cartilage and growth plate. 
Cylindrical samples of injected bone possessed a mean 
compressive modulus of 180 MPa, compared to 81 MPa for 
controls (p<0.001 ). Yield stress was also significantly higher 
40 more loosely packed HA microstructure. Additionally, there 
may exist a critical threshold for particle size, below which 
significant mechanical benefits occur in a composite (Fu 
S-Y, Feng X-Q, Lauke B, Mai Y-W. Effects of particle size, 
particle/matrix interface adhesion and particle loading on 
45 mechanical properties of particulate-polymer composites. 
Composites Part B: Engineering 2008; 39(6):933-961). 
Scaffolds with a higher NHA and MHA packing capacity 
could potentially be created by increasing PLGA concen-
tration in the PLGA/NMP solution (Guan L, Davies J E. 
50 Preparation and characterization of a highly macroporous 
biodegradable composite tissue engineering scaffold. Jour-
nal of Biomedical Materials Research Part A 2004; 71A(3): 
480-487), however, this would also increase the viscosity of 
the injectable mixture (Gad H, El-Nabarawi M, Abd El-
55 Hady S. Formulation and Evaluation of PLA and PLGA in 
Situ Implants Containing Secnidazole and/or Doxycycline 
for Treatment of Periodontitis. AAPS PharmSciTech 2008; 
9(3):878-884). 
An in situ forming HA-PLGA-PBAE implant offers sev-
60 era! advantages over traditional orthopedic injectables, such 
as poly(methyl methacrylate) (PMMA) bone cement. The 
heat of free radical polymerization of PMMA in situ can lead 
to protein denaturation and tissue necrosis (DiPisa Ja Fau-
Sih G S, Sih Gs Fau-Berman A T, Berman A T. The 
65 temperature problem at the bone-acrylic cement interface of 
the total hip replacement. Clinical Orthopaedics and Related 
Research 1976; 121:95-98), whereas in situ forming PLGA 
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scaffolds are formed via solvent exchange at ambient tem-
perature. PMMA is not biodegradable, while PLGA 
degrades hydrolytically over a time period dependent on its 
chemical properties (Kenley RA, Lee M 0, Mahoney T R, 
Sanders L M. Poly(lactide-co-glycolide) decomposition 5 
kinetics in vivo and in vitro. Macromolecules 1987; 20(10): 
2398-2403), Biodegradation is important for a drug delivery 
scaffold embedded in a trabecular network, where removal 
surgery is impossible and a permanent implant is not ideal. 
Finally, the mechanical properties of PMMA are a better 10 
match for cortical bone than a trabecular bone network, 
while PLGA is a less stiff material that may be appropriately 
augmented to match trabecular bone via addition of HA filler 
(Saha S, Pal S. Mechanical properties of bone cement: A 
review. Journal of Biomedical Materials Research 1984; 15 
18(4):435-462; Rezwan K, Chen Q Z, Blaker J J, Boccaccini 
AR. Biodegradable and bioactive porous polymer/inorganic 
composite scaffolds for bone tissue engineering. Biomate-
rials 2006; 27(18):3413-3431). An implant that acutely 
reinforces compromised bone, controls drug release, and 20 
gradually degrades to allow regeneration of native tissue can 
provide a comprehensive treatment in a single injection. 
Interestingly, scaffolds prepared with equal amounts of 
NHA and MHA tended to possess comparable mechanical 
properties to scaffolds prepared with pure NHA or pure 25 
MHA. This similarity may be due to the tight packing of 
NHA in the spaces between MHA particles, resulting in 
scaffolds that are effectively identical to tightly packed NHA 
when compressed. Ultimately, the similarity between pure 
NHA and equally mixed NHA/MHA scaffolds is probably 30 
the result of two factors: 1) HA should be present at 
sufficient concentrations so that load is primarily being 
transmitted between tightly packed HA particles, and 2) 
enough PLGA should be present so that it can bind all the 
HA particles together. For a system intended for intraosse- 35 
ous injection, however, 30% NHA provides the highest 
mechanical properties at the lowest total HA concentration, 
and was therefore the most appealing formulation in terms 
of injectability. 
Native trabecular bone in human femoral heads has a 40 
30 
which are both within the range of trabecular bone. Although 
in situ forming PLGA systems have not been extensively 
investigated for their mechanical properties, the strength of 
these scaffolds is 10-fold higher than a similar system 
containing 33% a-tricalcium phosphate and PLGA of a 
lower molecular weight (Schloegl W, Marschall V, Witting 
MY, Volkmer E, Drosse I, Leicht U, Schieker M, Wiggen-
horn M, Schaubhut F, Zahier S and others. Porosity and 
mechanically optimized PLGA based in situ hardening sys-
tems. European Journal of Pharmaceutics and Biopharma-
ceutics 2012; 82(3):554-562). Furthermore, the yield stress 
was on the higher end of healthy trabecular bone, so even if 
scaffolds are slightly less stiff than the native bone tissue, 
they can withstand similar stresses to healthy bone before 
beginning to collapse. It is important to consider these 
scaffolds as a means for temporary augmentation that can 
acutely preserve bone while treatment occurs, not as a 
replacement for healthy bone tissue. For this purpose, the 
material properties of the 30% NHA system are sufficient. 
Injectability is a unique concern for in situ forming 
scaffolds, because both HA and PBAE particle additives 
increase viscosity. Because prior injectable PLGA systems 
were not intended for mechanical support, and drug is 
usually mixed freely into the polymer solution, viscosity has 
not been a limiting factor when designing these systems. 
However, injectable bone cements and fillers have encoun-
tered issues with injectability because they are composed of 
a liquid phase containing high concentrations of suspended 
particles (Bohner M, Baroud G. Injectability of calcium 
phosphate pastes. Biomaterials 2005; 26(13):1553-1563; 
Alves H L, Santos LA, Bergmann C P. Injectability evalu-
ation of tricalcium phosphate bone cement. J Mater Sci: 
Mater Med 2008; 19(5):2241-2246). For example, decreas-
ing the liquid to powder ratio increases the required injection 
force and decreases the extruded fraction (Khairoun I, 
Boltong M G, Driessens F C M, Planell J A. Some factors 
controlling the injectability of calcium phosphate bone 
cements. J Mater Sci: Mater Med 1998; 9(8):425-428; 
Bohner M, Baroud G. Injectability of calcium phosphate 
pastes. Biomaterials 2005; 26(13):1553-1563), which is 
roughly analogous to increasing HA content in an injectable 
PLGA system. Various additives have been investigated to 
decrease the required injection force (Leroux L, Hatim Z, 
Freche M, Lacout J L. Effects of various adjuvants (lactic 
wide range of mechanical properties, with compressive 
moduli ranging from 100-600 MPa and yield strength rang-
ing from 1-9 MPa (Li B, Aspden R M. Composition and 
mechanical properties of cancellous bone from the femoral 
head of patients with osteoporosis or osteoarthritis. Journal 
of Bone and Mineral Research 1997; 12( 4):641-651; Schoe-
nfeld C M, Lautenschlager E P, Meyer P R, Jr. Mechanical 
properties of human cancellous bone in the femoral head. 
Med & biol Engng 1974; 12(3):313-317). For conditions 
that may be candidates for an injectable, intraosseous treat-
ment, these values may be reduced by 24% (yield stress) and 
20% (modulus) in osteoporotic patients (Li B, Aspden RM. 
Composition and mechanical properties of cancellous bone 
from the femoral head of patients with osteoporosis or 
osteoarthritis. Journal of Bone and Mineral Research 1997; 
12(4):641-651), or 50% (yield stress) and 72% (modulus) in 
osteonecrosis patients (Schoenfeld C M, Lautenschlager E P, 
Meyer P R, Jr. Mechanical properties of human cancellous 
bone in the femoral head. Med & biol Engng 1974; 12(3): 
313-317). Scaffolds with material properties similar to tra-
becular bone can aid load-bearing while the drug delivery 
component of the scaffold exerts its effect (Rezwan K, Chen 
Q Z, Blaker J J, Boccaccini AR. Biodegradable and bioac-
tive porous polymer/inorganic composite scaffolds for bone 
tissue engineering. Biomaterials 2006; 27(18):3413-3431). 
The average modulus of scaffolds prepared with 30% NHA 
was 141 MPa, and the average yield stress was 6.2 MPa, 
45 acid, glycerol, and chitosan) on the injectability of a calcium 
phosphate cement. Bone 1999; 25(2, Supplement 1):31S-
34S). Injectability will likely be a persistent, nontrivial issue 
for in situ forming PLGA systems containing mechanical 
filler. Setting NHA content to a constant 30% and varying 
50 PBAE microparticle content revealed that there is a clear 
limit on PBAE microparticle content (and, therefore, drug 
loading) beyond which the system cannot be injected with-
out exceeding limits of injection force or injection time. 
Longer-duration injections may be complicated by the pre-
55 cipitation of PLGA into a solid (Kempe S, Metz H, Mader 
K. Do in situ forming PLG/NMP implants behave similar in 
vitro and in vivo? A non-invasive and quantitative EPR 
investigation on the mechanisms of the implant formation 
process. Journal of Controlled Release 2008; 130(3):220-
60 225), leading to increased backpressure and a loss of inject-
ability, while injections requiring large sustained force may 
be uncomfortable for the surgeon performing the procedure. 
The injection force limit may be circumvented by the use of 
an injection gun, which would improve injection time and 
65 greatly increase the injection force limit. 
The space-filling and mechanical reinforcement potential 
of an injectable system is likely to differ in situ from 
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Thus, macromer made by reacting PEG400DA with isobu-
tylamine for 48 hours was termed H6. A macromer contain-
ing a 2:1 molar ratio of diethylene glycol diacrylate: 
simulated tests, due to the presence of a constrained geom-
etry filled with marrow and bordered by anatomical features 
such as articular cartilage, cortical bone, and the growth 
plate. The incomplete filling of free volume by the scaffold 
suggests that the material establishes flow channels of low 
resistance, resulting in small pockets of unfilled bone. 
MicroCT images and cylindrical tissue samples, however, 
show that these unfilled regions are distributed throughout 
the bony network, and the scaffold was capable of filling the 
bone tissue in all directions. Furthermore, injected bone 
tissue was significantly stronger and stiffer than native 
tissue, suggesting that the 58% filling that was achieved is 
sufficient to greatly improve mechanical properties of tra-
becular bone. 
PEG400DA was also created and will subsequently be 
5 referred to as AH6. The ratio of total acrylate to amine 
reactive groups was 1.2:1 for both macromers. 
PBAE hydrogels were formed by adding 0.1% w/w 
DMPA, dissolved in ethanol, to the macromer, pipetting this 
mixture between two parallel glass plates, and exposing the 
10 mixture to a 365 nm UV flood source for 5 minutes to 
crosslink the macromer. The resulting hydrogels were 
washed overnight in ethanol to remove residual DMPA and 
unreacted monomers and then stored in a desiccator until 
Conclusions 
The present study demonstrated the feasibility of an 
injectable PLGA scaffold containing PBAE and HA particles 
15 
use. 
PBAE microparticles were made by swelling PBAE 
hydrogels in ethanol for 1 hour and then grinding them with 
a mortar and pestle. The slurry was passed through a 250 µm 
sieve using an ethanol wash, and any larger particles were 
re-ground until 100% of the hydro gel was sieved. The 
as a mechanically supportive, in situ forming scaffold. 
Injectable scaffold mixtures are capable of being injected 
through a standard bone biopsy needle, infiltrating trabecu-
lar bone, then solidifying to produce scaffolds with mechani-
20 microparticle slurry was lyophilized, and the resulting 
microparticles were stored in a desiccator. 
Injectable Mixture Formulations 
A PLGA solution was formed by dissolving 30% or 40% 
w/w of either HMW or LMW PLGA in NMP overnight. 
25 PBAE microparticles (H6, AH6, or a mixture of the two) 
were added to the PLGA solution at 10% w/w and stirred 
cal properties comparable to those of trabecular bone. This 
injectable scaffold offers a promising treatment platform for 
ailments requiring both drug delivery and mechanical rein-
forcement of trabecular bone, and it has the advantage of 
being easily injectable and fully resorbable. This particular 
system was optimized to accommodate NHA mechanical 
filler and PBAE microparticles for drug delivery, with the 
goal of an intraosseous injection into the femoral head. In 
situ forming PLGA systems have traditionally been viewed 30 
purely as drug delivery devices, but this study clearly 
demonstrates the potential for a mechanical component to 
these systems as well. 
until the mixture was homogeneous. Simvastatin or doxy-
cycline (2% w/w individually or 2% w/w each for co-
delivery) were added to the PLGA-PBAE-NMP suspension 
and mixed thoroughly. Alternatively, doxycycline was pre-
loaded into AH6 microparticles by swelling the micropar-
ticles with a 3 mg/mL doxycycline solution in acetone at a 
ratio of 100 mg AH6 to 500 µL of solution. These swollen 
particles were lyophilized for 24 hours, resulting in doxy-
Example 3 
Poly(~-amino ester) (PBAE) hydrogel microparticles 
were incorporated into a PLGA matrix to provide several 
new functions: mechanical support, porosity, space-filling, 
and controlled co-delivery of antibiotics and osteogenic 
drugs. PBAE-containing PLGA ISis are more effective 
space-filling scaffolds and offer improved release kinetics 
compared to existing ISis used to treat periodontitis. 
Materials 
35 cycline pre-loaded into AH6 microparticles. Pre-loadedAH6 
microparticles at 10% w/w in PLGA solutions were then 
used in drug release studies. HMW formulations containing 
simvastatin were tested first, and the most promising mix-
tures were used in subsequent tests with doxycycline and/or 
40 LMW PLGA. Table 1 contains a list of all scaffold formu-
Diethylene glycol diacrylate and poly(ethylene glycol) 45 
400 diacrylate (PEG400DA) were bought from Poly-
sciences, Inc. (Warrington, Pa.). High molecular weight 
PLGA (HMW PLGA; 50:50 lactide:glycolide, 0.55-0.75 
dL/g in hexafluoroisopropanol, carboxylate-terminated) and 
low molecular weight PLGA (LMW PLGA; 50:50 lactide: 
glycolide, 0.15-0.25 dL/g in hexafluoroisopropanol, car-
boxylate-terminated) were purchased from DURECT (Bir-
mingham, Ala.). 2,2-Dimethoxy-2-phenylacetophenone 
(DMPA), N-methyl-2-pyrrolidone (NMP), gelatin (from 
porcine skin, type A), glutaraldehyde (25%, grade I), aga-
rose, trifluoroacetic acid (TFA), doxycycline hyclate, and 
glycine were obtained from Sigma Aldrich (St. Louis, Mo.). 
Simvastatin was from Haorui Pharma-Chem (Edison, N.J.). 
PBAE Hydrogel Preparation 
50 
55 
PBAE macromer was synthesized by reacting diacrylate 60 
with isobutylamine at 85° C. for 48 hours. Macromers were 
named according to the classification system from Anderson 
et al., in which the letter corresponds to a specific diacrylate 
and the number corresponds to a specific amine (Anderson 
D G, Tweedie CA, Hossain N, Navarro SM, Brey D M, Van 65 
Vliet K J, et al. A combinatorial library of photocrosslink-
able and degradable materials. Adv Mater 2006; 18:2614-8). 
lations that were examined for the drug release studies. 
TABLE 1 
Scaffold formulations investigated for drug release. 
Scaffold Name PLGA PLGA% PBAE Drugs 
HMW-AH HMW 30 AH6 S/D/S + D/D(Pre) 
HMW-H HMW 30 H6 s 
HMW-H/AH HMW 30 AH6 + H6 s 
BMW-Control HMW 30 None SID 
LMW-AH LMW 30 AH6 S/D/S + D 
LMW-Control LMW 30 None S/D/S + D 
40LMW-AH LMW 40 AH6 S/D/S + D/D(Pre) 
40LMW-Control LMW 40 None S/D/S + D/D(Pre) 
Abbreviations: 
S = simvastatin; 
D = doxycycline. 
(Pre) indicates drug was pre-loaded into PBAE microparticles, and 
"+" indicates co-delivery of drugs from the same scaffold. 
Microarchitecture and Mass Change 
To observe changes in ISI mass and microarchitecture, the 
following drug-free formulations were prepared: HMW-AH, 
HMW-H, HMW-H/AH, HMW-Control, LMW-AH, and 
LMW-Control (Table 1). In a 96-well plate, approximately 
10 mg of injectable scaffold mixture were injected dropwise 
from an 18-gauge needle into 300 µL of phosphate-buffered 
saline (PBS), pH 7.4. The syringe was weighed after each 
US 10,682,442 B2 
33 
injection to calculate the mass of each scaffold. PBS was 
replaced daily to prevent buildup of degradation byproducts. 
At each time point, 3 scaffolds from each group were 
removed, dabbed dry, and weighed to measure the wet mass. 
For HMW scaffolds, samples were collected at 1 and 5 days 5 
following the injection and then every 5 days thereafter. For 
LMW scaffolds, samples were collected at 1 and 2 days and 
then every other day afterward. All collected ISis were 
lyophilized for 24 hours and weighed again to determine dry 
mass. HMW scaffolds were then scanned using a SCANCO 10 
MicroCT 40 (SCANCO Medical AG, Switzerland) with 
X-ray parameters of 55 kV and 145 mA, and a 6 µm voxel 
size. A built-in bone trabecular morphometry analysis tool 
was used to create 3-D reconstructions, and measurements 
of porosity, mean pore size, and material density were 15 
conducted. To quantify accessible volume and surface area, 
simulated mercury intrusion porosimetry was run on the 3-D 
reconstructions using an included script. At select time 
points, samples were freeze-fractured, and a Hitachi S-4300 
scanning electron microscope (SEM) at 4 kV accelerating 20 




supematant:ethanol ratio to dissolve any precipitated simv-
astatin prior to HPLC analysis. Doxycycline was assayed 
using a mobile phase composed of 30% acetonitrile/70% 




BMW-Controls exhibited little dry mass change through 
the first 15 days of degradation, after which a linear decrease 
in mass of 4.8%/day occurred through day 30 (FIG. 19A). A 
significant (p<0.05) decrease in mass was observed at each 
time point from day 20 and onward. Over the first 5 days, the 
wet mass of these scaffolds decreased significantly (p<0.05) 
at a rate of 9.4%/day and then increased slightly between 
days 10 and 20, before gradually declining through day 35, 
although none of these later changes was significant (FIG. 
19B). Both HMW-AH and HMW-H/AH scaffolds exhibited 
a small wet mass loss in the first day, followed by a relatively 
linear 6.5%/day wet mass increase through day 30 to a 
maximum of273% of original mass. At day 35, scaffolds fell 
apart upon handling, and measurable mass decreased to 93% 
of the initial value. HMW-H scaffolds had a larger wet mass 
loss of37% (p<0.05) after 1 day, and between days 5 and 25, 
an 8.6%/day mass increase occurred. A plateau was reached All mechanical tests were performed with a Bose ELF 
3300 system. Gelatin slabs (20%) measuring 8 mm thick 
were crosslinked by overnight immersion in 5 mM glutar-
aldehyde. Unreacted aldehyde groups were quenched by 
placing the crosslinked gelatin slabs in a 50 mM glycine 
solution for 2 hours followed by serial washing with deion-
ized water. Cylindrical samples (4 mm in diameter) were 
punched out of the slabs, and their mechanical properties 
were characterized by compressing these cylindrical 
samples to 10% strain at a frequency of 1 Hz for 30 seconds 
25 between days 25 and 30 prior to a large decrease in mass at 
day 35. After a 1-day dry mass loss of 12%, HMW-AH 
scaffolds lost mass at a rate of 1.7%/day until day 10. Mass 
loss resumed at day 15 and continued at a rate of0.87%/day 
until day 30. HMW-H/AH scaffolds had a dry mass loss of 
30 26% after day 1, and no significant mass change followed 
through day 30. Similarly, HMW-H scaffolds exhibited a 
large initial dry mass loss of 38% after 1 day, and no 
significant subsequent mass loss occurred until day 30 
(p<0.05). 
LMW-Controls exhibited a gradual dry mass decrease to 
89% after 8 days, after which the mass decreased linearly at 
a rate of 3%/day through day 30 (FIG. 19C). LMW-Control 
wet mass rapidly increased to 193% through the first 5 days, 
then sharply declined and fluctuated around 150% through 
40 day 16 (FIG. 19D). Beyond day 16, a linear mass loss of 
7%/day occurred through day 30. LMW-AH scaffolds 
decreased steadily in dry mass at a rate of 5%/day for the 
first 8 days, followed by a brief plateau through 12 days, and 
terminating with a linear mass loss of 2%/day through day 
to mimic chewing conditions (Goktas S, Dmytryk J J, 
Mcfetridge PS. Biomechanical behavior of oral soft tissues. 35 
J Periodontol 2011; 82: 1178-86). The slabs containing cylin-
drical holes were used as molds to inject both HMW and 
LMW Control and AH-containing scaffolds. After injection, 
the molds were capped with 2% agarose slabs, lightly 
clamped shut to prevent extrusion of material due to swell-
ing, and immersed in PBS. After 3, 6, 9, 12, or 15 days, the 
solidified samples within the molds were subjected to com-
pression at a displacement rate of 0.5 mm/sec. The interfa-
cial shear strength required for push-out was calculated by 
dividing the maximum push-out force by the scaffold sur-
face area in contact with the mold. Cylindrical scaffolds that 
had been pushed out of their molds were tested for their 
compressive properties under 1 % strain triangular waves 
applied at a frequency of 1 Hz for 60 seconds. The initial 
modulus was determined from the first compression cycle, 
and the equilibrium modulus was measured during the final 
cycle. Resilience was calculated by integrating the linear 
region of the stress-strain curve. These methods followed 
protocols established to measure the mechanical properties 
45 30. LMW-AH wet mass increased for the first 5 days and 
plateaued, fluctuating around 150% through day 16. After 
day 16, a mass loss of 7%/day occurred through day 30. 
Microarchitecture 
LMW samples were unable to be analyzed using microCT 
50 due to their fragility following lyophilization, resulting in 
structural collapse and unreliable scan data. The microarchi-
tecture of BMW-Controls changed dramatically throughout 
the first 15 days of degradation, leading to collapse, while 
HMW ISis containing PBAE additives possessed a more 
of gingival tissue (Goktas S, Dmytryk J J, Mcfetridge P S. 
Biomechanical behavior of oral soft tissues. J Periodontal 
2011; 82: 1178-86). 
Drug Release 
Approximately 100 mg of each mixture (Table 1) were 
injected dropwise into 1 mL PBS, where the PLGA rapidly 
solidified into droplet-shaped scaffolds. At each time point, 
supernatant was entirely removed, stored in a refrigerator, 
and replaced with fresh PBS. A Hitachi Primaide HPLC 
system with a Kinetex C18 colunm was run isocratically at 
1 mL/min with a mobile phase composed of 70% acetoni-
trile/30% water+0.1 % TFA to detect simvastatin at 240 nm. 
Collected supernatant was mixed with ethanol at a 2: 1 
55 uniform pore structure and swelled visibly throughout the 15 
day period (FIG. 20). After 1 day, BMW-Controls were 
composed of a dense solid phase with large, homogeneously 
distributed spherical pores with diameters on the order of0.5 
mm to 2 mm. By day 5, some large pores remained in the 
60 core of the scaffold, while most were present near the edges 
and were oriented radially. By day 10, the radial pores were 
more numerous, surrounding the dense core, and by day 15, 
the scaffolds had collapsed. HMW-H scaffolds possessed a 
uniformly porous microarchitecture by day 1, and there were 
65 little microstructural changes until day 15, when noticeable 
swelling had occurred. At day 15, BMW-Controls had a 
17% increase over initial volume, while HMW-H, HMW-
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reduced to 0.5 kPa by day 12 (p<0.05). The interfacial 
strength of HMW-AH samples increased significantly from 
4.7 kPa at day 3 to 8.8 kPa at day 6 (p<0.01), and the 
interfacial strength continued to increase, although not sig-
nificantly, to 11 kPa by day 15. At every time point, the 
interfacial strength of HMW-AH significantly exceeded that 
of BMW-Controls (p<0.001). 
HI AH, and HMW-AH had increases of 33%, 84%, and 95%, 
respectively. HMW-AH and HMW-H/AH scaffolds both 
initially possessed porous networks with radiopaque regions 
inside these pores, which is indicative of non-degraded 
PBAE material (FIG. 2, arrows). By day 5, scaffolds were 5 
noticeably swollen, and there was little evidence of non-
degraded PBAE material, resulting in a uniformly porous 
microarchitecture; swelling increased progressively through 
day 15. None of the scaffolds containing PBAE additives 
collapsed within the 15-day period. 
HMW ISis generally increased in both porosity (FIG. 
21A) and volume (FIG. 21B) as they degraded. Specifically, 
BMW-Controls initially possessed 24% porosity, which 
increased to a maximum of54% at day 10, and then declined 
slightly to 46% by day 15. All PBAE-containing scaffolds 15 
steadily increased throughout the 15-day period, with initial 
porosities ranging from 42% (HMW-AH) to 55% (HMW-
H). All PBAE-containing ISis possessed significantly higher 
porosities than BMW-Controls at all time points (p<0.001). 
Among PBAE-containing ISis, only HMW-AH at day 1 20 
differed significantly in porosity from others. Scaffold vol-
ume, normalized to initial mass, showed that BMW-Con-
trols increased slightly in volume by day 5 before gradually 
declining (FIG. 21B), and had significantly lower volume 
than all PBAE groups throughout degradation (p<0.01). 25 
HMW-H exhibited an initial decrease in scaffold volume 
between days 1 and 5, followed by a linear increase beyond 
the initial volume by day 15. Both HMW-AH and HMW-
LMW samples exhibited a less dramatic difference 
between AH and Control groups (FIG. 22). The interfacial 
10 strength for LMW-Controls remained significantly higher 
than BMW-Controls and lower than HMW-AH at all time 
points (p<0.01), with interfacial strengths ranging from 2.7 
to 5 kPa. LMW-AH interfacial strength increased from 5.2 
kPa at day 3 to 8.7 kPa by day 9, and then decreased down 
to 5.3 kPa by day 15. LMW-AH samples possessed signifi-
cantly higher interfacial strength than did LMW-Controls for 
the first 12 days tested (p<0.005), and the interface remained 
similar to that for HMW-AH samples until days 12 and 14, 
which were both significantly lower than corresponding 
HMW-AH interfacial strengths (p<0.01). Both BMW-Con-
trol and HMW-AH cylindrical samples exhibited initial and 
30-cycle compressive moduli that remained unchanged 
through the first 9 days, followed by a decrease through day 
15 (FIG. 23A). For BMW-Controls, initial modulus ranged 
between 48 and 61 MPa through the first 12 days, and then 
a significant decrease to 25 MPa occurred (p<0.01). Signifi-
cant changes in HMW-AH samples were detected only 
between day 15 and days 6 or 9 (p<0.05), and over the 
15-day period, these moduli ranged from a minimum of 14 H/ AH generally increased in volume throughout the 15 day 
period. 30 MPa at day 15 to 29 MPa at day 9. The 30-cycle modulus 
of BMW-Controls did not change for the first 9 days, with 
moduli ranging from 94 to 102 MPa. Significant decreases 
occurred at day 12, to 58 MPa, and at day 15, to 17 MPa 
Accessible volume was measured for various simulated 
penetrating sphere diameters ranging from 12 µm to 120 µm, 
and the volume accessible by a 24 µm sphere was compared 
between groups over 15 days (FIG. 21C). This diameter 
approximates the size of the progenitor cells that may 35 
migrate into these pores (Izumi K, Tobita T, Feinberg S E. 
Isolation of human oral keratinocyte progenitor/stem cells. J 
Dent Res 2007; 86:341-6; Lavenus S, Pilet P, Guicheux J, 
Weiss P, Louam G, Layrolle P. Behaviour of mesenchymal 
stem cells, fibroblasts and osteoblasts on smooth surfaces. 40 
Acta Biomater 2011; 7:1525-34). At day 1, BMW-Control 
and HMW-AH possessed significantly lower accessible vol-
ume than did HMW-H and HMW-AH samples (p<0.01). At 
day 5 and beyond, all PBAE-containing ISis possessed 
similar accessible volumes, which increased from 34-38% at 45 
day 5 to 65-78% by day 15. From days 5 through 15, 
controls had significantly lower accessible volume 
(p<0.001). Accessible surface area was normalized to initial 
scaffold mass, and measured using the same 24 µm pen-
etrating sphere size (FIG. 21D). The trends for accessible 50 
surface area were similar to accessible volume, with HMW-
Control and HMW-AH initially possessing significantly 
lower values than HMW-H and HMW-AH (p<0.01). Con-
trols remained significantly lower than all other groups for 
each subsequent time point (p<0.001). HMW-AH increased 55 
linearly in accessible surface area through day 15 before 
plateauing, while both HMW-H/AH steadily increased in 
accessible surface area throughout degradation. HMW-H 
remained relatively unchanged between days 1-5 before 
increasing linearly through day 15. 
(p<0.0001). Modulus ranged from 24 MPa at day 3 to 34 
MPa by day 9, and then decreased significantly to 14 MPa 
by day 15 (p<0.001). The ratio of the initial to the 30-cycle 
modulus did not change significantly throughout the 15 day 
period for HMW-AH samples, and it ranged from 0.95 at 
day 15 to 1.16 at day 9 (FIG. 23B). For BMW-Controls, the 
modulus ratio ranged from 1.67 to 1.88 over the first 9 days, 
and then decreased significantly to 1.2 by day 12 and 0.7 by 
day 15 (p<0.01). 
Resilience of BMW-Controls and HMW-AH samples 
increased between days 3 and 6 before declining through 
day 15, and BMW-Controls exhibited the highest initial 
resilience and the lowest 30-cycle resilience (FIG. 23C). 
Resilience from the initial compression cycle of HMW-
Controls increased significantly from 1 J/m3 at day 3 to 3.1 
J/m3 at day 6 (p<0.0001 ), and then decreased significantly at 
day 12 to 0.97 J/m3 (p<0.0001). The 30-cycle resilience 
followed the same trend, with 0.35 J/m3 at day 3, which 
increased significantly to 0.9 J/m3 by day 6, and then 
dropped significantly to 0.25 J/m3 by day 12 (p<0.001). 
Through the first 12 days, the ratio of the initial to the 
30-cycle resilience ranged from 0.26 to 0.33, and a signifi-
cant decrease occurred between days 9 and 15, down to 0.15 
(p<0.05) (FIG. 23D). HMW-AH initial resilience increased 
significantly between days 3 and 6, from 0.73 to 1.7 J/m3 
(p<0.001). The resilience did not change until day 15, when 
Mechanical Properties 
The interfacial strength between ISI and cylindrical gela-
60 a significant decrease occurred from 1.53 J/m3 at day 9 to 
0.79 J/m3 at day 15 (p<0.01). The 30-cycle modulus of 
HMW-AH samples increased significantly from 0.46 J/m3 at 
day 3 to 1.28 J/m3 at day 6 (p<0.0001), with subsequent tin mold, as measured by maximum push-out force, 
decreased over 15 days for BMW-Controls but increased 
over the same period for HMW-AH (FIG. 22). For HMW- 65 
Controls, the interfacial strength was 1.2 kPa at 3 days, and 
then decreased relatively linearly until it was significantly 
significant decreases at day 12, to 0.83 J/m3 (p<0.01), and at 
day 15, to 0.52 J/m33 (p<0.05). The ratio of these two 
resilience values for HMW-AH samples did not change 
significantly throughout the 15 day period. 
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LMW-Controls possessed uniformly higher ratios of ini-
tial to 30-cycle modulus at each time point compared to 
LMW-AH, although this difference was significant at only 
days 3 and 12 (p<0.05) (FIG. 23F). Similar to HMW 
samples, LMW-AH samples exhibited an initial to 30-cycle 5 
modulus ratio ranging from 0.94 to 1.13. While LMW-
Control initial modulus increased steadily from 3.2 to 8.6 
MPa between days 3 and 12, LMW-AH initial modulus 
fluctuated from 3.7 to 12 MPa, with a maximum at 9 days 
and a minimum at 12 days, resulting in no clear trend (FIG. 10 
23E). The initial resilience of both LMW-AH and LMW-
Control was highest at day 12, and in all cases, the 30-cycle 
resilience was lower than the initial value for both LMW-
AH and LMW-Control (FIG. 23G). However, the ratio of 
15 
initial to 30-cycle resilience ofLMW-AH, ranging from 0.46 
to 0.56, was significantly higher at every time point than the 
same ratio for LMW-Control (p<0.05), which ranged from 
0.15 to 0.33 (FIG. SH). 
38 
loaded doxycycline, and after an initial 63% burst, release 
continued up to 87% by day 7. 
Discussion 
PBAE additives act as both porogens and drug delivery 
vehicles within the solid. PLGA ISI matrix. As porogens, the 
1-day mass loss of HMW-H and HMW-H/AH scaffolds 
indicated complete degradation of H6, which has an 
expected degradation time of 4-8 hours (Hawkins A M, 
Milbrandt TA, Puleo D A, Hilt J Z. Synthesis and analysis 
of degradation, mechanical and toxicity properties of poly 
(~-amino ester) degradable hydrogels. Acta Biomater 2011; 
7:1956-64), while both HMW-AH and LMW-AH scaffolds 
exhibited a gradual mass loss through 10 days, which is 
twice the 5 day in vitro degradation time of AH6 PBAEs 
(Hawkins A M, Tolbert M E, Newton B, Milbrandt T A, 
Puleo D A, Hilt J Z. Tuning biodegradable hydrogel prop-
erties via synthesis procedure. Polymer 2013; 54:4422-6). 
The difference is probably due to the PLGA matrix both 
Drug Release 20 limiting access of water to the embedded PBAE micropar-
ticles and physically preventing them from swelling, thus 
slowing degradation (Clark A, Milbrandt TA, Hilt J Z, Puleo 
DA. Mechanical properties and dual drug delivery appli-
HMW scaffolds loaded with simvastatin released the drug 
over 90 days, and scaffolds containing PBAE microparticles 
produced release profiles with distinct regions of different 
release rates (FIG. 24A). BMW-Controls exhibited a sig-
nificantly higher 1-day burst of36% (p<0.001) compared to 25 
all PBAE-containing groups, which had a burst of 6% or 
less. BMW-Controls exhibited a declining daily release rate 
over the course of 40 days, with residual simvastatin 
released over the last 40 days as scaffolds completely 
degraded. HMW-H exhibited a relatively linear release rate 30 
of 1 %/day through day 30, followed by a period of minimal 
release through day 60. HMW-AH had a release rate of 
2.8%/day for the first 13 days, followed by a period of 
1 %/day through day 30 and then 0.25%/day through day 50. 
HMW-H/AH had release rates of 2.1 %/day through day 13, 35 
1 %/day through day 30, and then 0.2%/day through day 50. 
Beyond day 60, the remaining drug was released through 
day 90 as scaffolds completely degraded. 
LMW scaffolds released simvastatin through 30 days, and 
AH6 microparticle additives reduced the burst for each 40 
formulation (FIG. 24B). LMW-Controls had 47% burst 
followed by a roughly linear release rate of 2.1 %/day 
through day 30. The burst was reduced to 21 % for 40LMW-
Controls, after which the release rate steadily declined 
through day 30. There was no difference in simvastatin 45 
release kinetics between LMW-AH scaffolds containing 
simvastatin alone or doxycycline and simvastatin together. 
Both LMW-AH and 40LMW-AH scaffolds had no appre-
ciable burst, and linear release rates ranged from 2.3 to 
2.5%/day through days 24 and 26, respectively. After day 24 50 
or 26, the release rate increased to 10%/day until all drug 
was released. 
Doxycycline exhibited similar release patterns from both 
HMW (FIG. 25A) and LMW ISis (FIG. 25B), with no 
difference observed between PBAE-containing scaffolds 55 
and controls. Pre-loading doxycycline into PBAE micropar-
ticles resulted in a 1-day burst similar to controls, but with 
significantly more drug released over the remainder of the 
week. In all cases where the antibiotic was not pre-loaded 
into AH6 microparticles, release plateaued within one or two 60 
days, and drug was released incrementally for the remainder 
of the monitored period. In all HMW ISis tested, release 
plateaued at approximately 70% of total drug, and pre-
loaded doxycycline released an additional 28% over the 
following 6 days. For LMW ISis, the plateau ranged from 65 
86-95% for 30% PLGA and from 63-74% in 40% PLGA. 
ISis containing 40% LMW PLGA were tested with pre-
cation of poly(lactic-co-glycolic acid) scaffolds fabricated 
with a poly(~-amino ester) porogen. Acta Biomater 2014; 
10:2125-32; Hawkins AM, Milbrandt TA, Puleo DA, Hilt 
J Z. Composite hydrogel scaffolds with controlled pore 
opening via biodegradable hydrogel porogen degradation. J 
Biomed Mater Res A 2014; 102:400-12). There is evidence 
that PBAE swelling is restricted by comparing the microCT 
cutplanes and implant volumes between groups, in which 
HMW-H, which contains the most hydrophilic PBAE, 
swelled more gradually and to a smaller degree than HMW-
AH and HMW-H/AH formulations. Theoretically, H6 
should achieve greater maximum swelling than AH6, and 
the maximum swelling point should occur at 4 and 36 hours, 
respectively (Spencer D. Oswald physical and engineering 
sciences second place: multiple macromer hydrogels for 
multiphase drug release. Kaleidoscope 2014; 11:20). 
HMW-H scaffolds likely delayed degradation of the PBAE 
as well, however, the daily sampling frequency would not 
detect a difference unless the degradation period of H6, 
which typically degrades in 4-8 hours (Hawkins A M, 
Milbrandt TA, Puleo D A, Hilt J Z. Synthesis and analysis 
of degradation, mechanical and toxicity properties of poly 
(~-amino ester) degradable hydrogels. Acta Biomater 2011; 
7:1956-64), was prolonged beyond 24 hours. The failure of 
BMW-Controls to swell beyond their initial mass suggests 
that the loss ofNMP during precipitation exceeded the water 
uptake of the scaffolds. Conversely, LMW-Controls were 
capable of entrapping water in the core of the scaffolds due 
to their less hydrophobic nature, and the rapid decrease in 
wet mass after day 3 was caused by the fragile PLGA skin 
rupturing, allowing the entrapped buffer to leak out. Inter-
estingly, all HMW scaffolds containing PBAE micropar-
ticles swelled up to 250% of their original mass over a 
period of30 days, while comparable LMW scaffolds swelled 
to a maximum of 150%. Again, LMW scaffolds were prone 
to rupture, which would allow water to escape, while the 
HMW scaffolds remained structurally intact as they swelled 
and therefore maintained a larger water capacity. Prior 
research on similar systems containing porogens such as 
sucrose or sodium chloride did not show such a dramatic 
mass changes (Krebs M D, Sutter KA, Lin A S P, Guldberg 
R E, Alsberg E. Injectable poly(lactic-co-glycolic) acid 
scaffolds with in situ pore formation for tissue engineering. 
Acta Biomater 2009; 5:2847-59), which suggests that the 
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swelling behavior of PBAE hydrogel particles has a more 
profound effect on water uptake and retention than tradi-
tional porogens. 
40 
remains negligible. On the other hand, AH hydrogels were 
observed to swell beyond 200% of their initial mass within 
2 days in PBS (data not shown), and although this effect is 
PBAE microparticles also influence macro- and micro-
structural changes of ISis as they degrade. BMW-Controls 5 
possessed surface-adjacent smaller pores and centrally-lo-
cated macropores, which is typical of these implants because 
PLGA at the surface tends to precipitate rapidly, while the 
interior precipitates more gradually, allowing voids to 
coalesce (Astaneh R, Erfan M, Moghimi H, Mobedi H. 10 
Changes in morphology of in situ forming PLGA implant 
prepared by different polymer molecular weight and its 
effect on release behavior. J Phann Sci 2009; 98:135-45). 
PBAE microparticles caused the ISis to adopt a porous 
network microarchitecture with no difference between sur- 15 
probably muted due to the physical constraint within the 
PLGA matrix, there is enough of an effect to provide 4 to 
10-fold higher interfacial strength than controls. Preliminary 
studies also showed no measurable adhesion between the 
gelatin surface and the implants (data not shown), so any 
differences in interfacial strength should be solely a result of 
the superior space-filling due to swelling of HMW-AH 
implants. LMW-AH scaffolds exhibited a similar benefit 
compared to LMW-Controls, although this difference was 
less pronounced due to the natural swelling behavior of 
LMW-Controls, which increased interfacial strength, and 
the rapid degradation of material, which caused both LMW-
Controls and LMW-AH to decrease in strength over the 15 face or central pore sizes, because the homogeneous distri-
bution of hydrogel microparticles acted as a template for 
uniform PLGA precipitation. This hypothesis is supported 
by the rapid swelling and increase in accessible volume 
observed in all PBAE-containing ISis. The lack of collapse 
in HMW-AH, -H, or -H/AH implants implies that these 
homogeneously distributed hydrogel particles also played a 
role in structurally stabilizing the scaffolds. In BMW-Con-
trols, the largest pores collapsed, whereas PBAE-containing 
scaffolds, with their uniform microarchitectures, were able 
to distribute stresses throughout the PLGA matrix and avoid 
collapse. It has been previously demonstrated that varying 
the size and distribution of pores can dramatically alter 
mechanical properties of materials (Li H, Oppenheimer S M, 
Stupp S I, Dunand D C, Brinson L C. Effects of pore 
morphology and bone ingrowth on mechanical properties of 
microporous titanium as an orthopaedic implant material. 
Mater Trans 2004; 45:1124-31; Yu H, Matthew H W, 
Wooley P H, Yang S-Y. Effect of porosity and pore size on 
microstructures and mechanical properties of poly-E-capro-
lactone-hydroxyapatite composites. J Biomed Mater Res B 
Appl Biomater 2008; 866:541-7). The lattice-like PLGA 
network of PBAE-containing implants may also help 
explain the sustained mechanical resilience observed for 
HMW-AH implants even after the degradation period of the 
PBAE had passed. The increased porosity and accessible 
surface area of PBAE-containing ISis offers many advan-
tages when considering PLGA ISis as potential scaffolds 
rather than simply drug delivery devices. In pre-formed 
PLGA scaffolds, larger accessible volume and surface area 
provide more opportunity for tissue ingrowth, and it is 
anticipated that PLGA ISis will behave similarly in future 
cell culture or in vivo testing. 
A persistent issue with antibiotic-releasing implants in 
periodontal applications is that the implant is not secure 
inside the periodontal pocket, which can lead to small pieces 
being dislodged as the implant moves within the space 
(Anderson H H. Treatment of chronic periodontitis: a site-
specific fiber placement technique. Pract Periodontics Aes-
thet Dent 1996; 8:565-70). Here, push-out forces were used 
to measure the interfacial strength between the implant 
surface and a simulated tissue pocket. The opposing trends 
observed in push-out force for BMW-Control compared to 
HMW-AH samples indicate that swelling of AH hydrogels 
can improve space-filling and pocket retention of implants. 
Even at the initial 3-day measurement, HMW-AH samples 
had significantly higher interfacial strength than controls, 
and this difference became even more pronounced as the 
incubation period increased. Although HMW PLGA does 
swell to a small degree as it degrades, this behavior is offset 
by the shrinkage of the implant during the precipitation 
phase, and the net result is that the interfacial strength 
day period. A scaffold that expands to fill its injection site as 
it solidifies is less likely to cause irritation due to movement 
within the pocket. Furthermore, more contact area between 
20 the implant and the tissue means that the released drug has 
a shorter path to enter the gingival tissue, and it has a smaller 
likelihood of being washed away due to exchange in the 
crevicular fluid. Little information is available on the mag-
nitude of stresses experienced within gingival soft tissue, but 
25 the periodontal ligament is the soft tissue responsible for 
transmitting chewing force between the tooth and the under-
lying alveolar bone (Andersen K L, Pedersen E H, Melsen 
B. Material parameters and stress profiles within the peri-
odontal ligament. Am J Orthod Dentofacial Orthop 1991; 
30 99:427-40; Beertsen W, McCulloch CA G, Sodek J. The 
periodontal ligament: a unique, multifunctional connective 
tissue. Periodontal 2000 1997; 13:20-40). Measurements of 
stress in oral mucosa! tissues under typical bite forces of 
denture wearers suggested that these tissues experience 
35 compressive stresses ranging from 5 to 40 kPa during 
chewing (Sawada A, Wakabayashi N, Ona M, Suzuki T. 
Viscoelasticity of human oral mucosa: implications for 
masticatory biomechanics. J Dent Res 2011; 90:590-5). 
According to these values, HMW-AH ISis have initial 
40 interfacial strengths within that range, and within 6 days the 
interfacial strength exceeds the stress generated by a soft 
bite. BMW-Controls at every time point possessed interfa-
cial strengths 1-2 orders of magnitude lower. These data 
suggest that patients receiving HMW-AH ISis may be able 
45 to chew food shortly after receiving treatment without 
danger of loosening the implant, while controls, which 
approximate clinically available treatments, are more easily 
loosened and dislodged. This swelling-based, space-filling 
approach is an alternative to other avenues that seek to 
50 reduce detachment by improving the adhesion between the 
polymer surface and surrounding tissue. In a separate study 
using a more adhesive components, increased bioadhesion 
was observed in the first several hours following injection 
into a simulated pocket (Do MP, Neut C, Delcourt E, Seixas 
55 Certo T, Siepmann J, Siepmann F. In situ forming implants 
for periodontitis treatment with improved adhesive proper-
ties. Eur J Pharm Biopharm 2014:[Epub ahead of print]), 
whereas the present PBAE-containing ISis were demon-
strated to improve pocket retention through a 15-day period. 
60 An interesting approach for future studies may be to incor-
porate both bioadhesive and swelling additives in order to 
provide acute attachment followed by prolonged space-
filling. 
Although these periodontal ISis are not designed as 
65 load-bearing structures, they are subject to stresses, primar-
ily due to chewing, which typically occurs at frequencies 
between 0.1 and 1 Hz in humans (Tanaka E, Yamana E, 
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Dalla-Bona DA, Watanabe M, Inubushi T, Shirakura M, et 
al. Dynamic compressive properties of the mandibular con-
dylar cartilage. J Dent Res 2006; 85:571-5). The gelatin 
molds used in push-out studies had similar compressive 
modulus compared to gingival tissues in order to simulate a 
periodontal pocket (Goktas S, Dmytryk J J, Mcfetridge PS. 
Biomechanical behavior of oral soft tissues. J Periodontal 
2011; 82: 1178-86). It has been proposed that less stiff 
implants may reduce irritation due to the presence of mate-
rial within the periodontal pocket (Qin Y, Yuan M, Li L, Li 
W, Xue J. Formulation and evaluation of in situ forming 
PLA implant containing tinidazole for the treatment of 
periodontitis. J Biomed Mater Res B Appl Biomater 2012; 
l00B:2197-202). PLGA deformed plastically and became 
stiffer under compression, even at low strains and only 30 
compression cycles, while the modulus of HMW-AH 
samples remained unchanged, indicating that PBAE addi-
tives preserve elasticity. In the commercially available Atri-
dox® system, a dressing or adhesive is used to keep the 
implant in place, but there is also the concern that repeated 
compression cycles can cause the implants to break apart, 
allowing pieces of material to cause local irritation or escape 
the periodontal pocket (Drisko C H. The use of locally-
delivered doxycycline in the treatment of periodontitis. 
Clinical results*. J Clin Periodontol 1998; 25:947-52; Kar-
imbux N. Clinical cases in periodontics. Chichester, West 
Sussex, UK: Wiley-Blackwell; 2012). Therefore, flossing 
and brushing are discouraged for up to a week following 
implantation, and patients are told to expect small pieces of 
material to break off (Drisko C H. The use of locally-
delivered doxycycline in the treatment of periodontitis. 
Clinical results*. J Clin Periodontal 1998; 25:947-52). 
Although neither control nor PBAE-containing ISis broke 
apart during the timeframe or compression cycles observed, 
the 30-cycle modulus of BMW-Controls was reduced dra-
matically between 9 and 15 days, and this difference would 
likely become more pronounced as time or compression 
cycles increased. HMW-AH samples were less stiff and 
retained their modulus throughout cyclic compression, 
which suggests they are more suitable to withstand the 
dynamic mechanical environment of the periodontal tissue. 
BMW-Controls and LMW-Controls were more resilient 
during the initial compression cycle, yet they were consis-
tently less resilient than corresponding AH-containing 
implants after 30 cycles, indicating that the PBAE hydrogel 
component helps preserve resilience. The lack of change for 
both modulus and resilience after cyclic loading is promis-
ing for the development of more mechanically suitable 
implants for the periodontal pocket. Dynamic mechanical 
analysis is required to assess viscoelastic properties for full 
lifespan of the implant, but this short-term cyclic compres-
sion data suggests that the addition of only 10% hydro gel 
particles can greatly improve the durability of these 
implants. As mentioned previously, the addition of PBAE 
microparticles led to a lattice-like PLGA microarchitecture, 
which should theoretically provide more resilience than the 
heterogeneous structure of the controls because there are no 
macropores, which appear to be the source of collapse in 
controls. Oral soft tissues have compressive moduli ranging 
from 0.2 to 8 MP, and typical dental materials used to fill 
these soft tissues after extractions or other procedures have 
moduli on the order of 1-20 MPa, which are both similar to 
the compressive properties of ISis developed here. 
Simvastatin release kinetics from both HMW and LMW 
ISis were highly dependent on PBAE microparticle content. 
The larger burst in controls can be attributed to simvastatin 
dissolved in the NMP phase being rapidly lost during solvent 
42 
exchange, which has been previously reported (Fisher P D, 
Palomino P, Milbrandt TA, Hilt J Z, Puleo D A. Improved 
small molecule drug release from in situ forming poly 
(lactic-co-glycolic acid) scaffolds incorporating poly(beta-
5 amino ester) and hydroxyapatite microparticles. J Biomater 
Sci Polym Ed 2014; 25:1174-93). Because these PBAEs 
swell in many organic solvents, such as NMP, acetone, and 
ethanol, PBAE microparticles become swollen with NMP 
and simvastatin during the mixing phase prior to injection. 
10 Simvastatin, which is freely soluble in NMP, is preferen-
tially taken up by PBAEs, which act as NMP sponges, while 
NMP-insoluble drugs such as doxycycline remain in the 
PLGA phase outside the swollen particles ( data not shown). 
These swollen microparticles act as an additional diffusive 
15 barrier to reduce initial burst of simvastatin, and once the 
initial hardening of the scaffold surface has occurred, sim-
vastatin release is governed by both diffusion and PBAE 
degradation. The degradation profile of AH6 microparticles 
is reflected in the accelerated release rate from AH- and 
20 H/AH-containing scaffolds through day 13. The release 
profile for HMW-H/AH ISis closely approximates the aver-
age of the HMW-H and HMW-AH curves, which suggests 
that the two hydrogels contribute independently to simvas-
tatin release kinetics, and the results of their contributions 
25 are additive. Simvastatin release kinetics were more strongly 
affected by PBAE microparticle content in 30% LMW 
PLGA scaffolds than in 40% LMW PLGA scaffolds, and this 
difference is attributable to multiple factors. First, the higher 
PLGA content formulation is more viscous, which allows 
30 more rapid formation of a protective "skin" that slows 
solvent exchange and thus burst release. Second, 40% LMW 
ISis contain more PLGA for equivalent injected masses 
when compared to 30% LMW ISis, which provides more 
polymer volume to entrap simvastatin, further limiting burst. 
35 Interestingly, AH6 degradation did not appear to accelerate 
simvastatin release in LMW scaffolds as dramatically as it 
did in HMW scaffolds for the first 10 days. This may be due 
to the faster degradation time and relatively lower hydro-
phobicity of LMW PLGA, which allows faster simvastatin 
40 release from the PLGA phase and masks the contribution of 
AH6-mediated release. 
Release kinetics of freely-mixed doxycycline from HMW 
and LMW ISis were unaffected by the addition of PBAE 
microparticles, however pre-loading doxycycline into AH6 
45 microparticles provided a measure of control. The lack of 
additional doxycycline release after the initial burst in freely 
mixed cases is probably due to the entrapment of remaining 
drug in the PLGA phase, and because doxycycline is sub-
stantially more hydrophilic than simvastatin, it has low 
50 mobility through the hydrophobic PLGA matrix. This pla-
teau effect is undesirable for antibiotic delivery, because 
bacteria surviving the initial burst will be free to re-colonize. 
By pre-loading doxycycline into AH6 PBAE microparticles, 
the initial burst was followed by continuous release of 
55 remaining drug through 1 week, which is consistent with 
systemic doxycycline regimens of 1 week following scaling 
and root planing. 
Conclusions 
PLGA ISis formulated with PBAE microparticle addi-
60 tives provide multiple advantages over existing periodontal 
ISis. These composite ISis are more resilient and are 
retained more firmly in simulated gingival tissue than PLGA 
alone, so there will be a lower risk of the implant deforming, 
loosening, and premature fragmentation, which is a concern 
65 with existing systems. Additionally, PBAE microparticles 
offer a secondary means of controlling drug release kinetics, 
and multiple drugs with independent release profiles can be 
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delivered, instead of the single-drug systems that are cur-
rently available. Future studies will focus on the potential of 
these PBAE-containing ISis to act as scaffolds for tissue 
regeneration, because the high porosity and open pore 
network is suitable for tissue ingrowth. 
The foregoing descriptions of various embodiments pro-
vide illustration of the inventive concepts. The descriptions 
are not intended to be exhaustive or to limit the disclosed 
invention to the precise form disclosed. Modifications or 
variations are also possible in light of the above teachings. 10 
The embodiments described above were chosen to provide 
the best application to thereby enable one of ordinary skill 
in the art to utilize the inventions in various embodiments 
and with various modifications as are suited to the particular 
use contemplated. All such modifications and variations are 15 
within the scope of the invention. All publications, patents 
and patent applications referenced herein are to be each 
individually considered to be incorporated by reference in 
their entirety. 
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3. The injectable system of claim 2, wherein the PLGA 
has a L:G ratio of between 50:50 and 95:5, a molecular 
weight between 5 and 300 kDa and an endcap of carboxylate 
or ester-crosslinked hydrocarbon. 
4. The injectable system of claim 1, wherein between 15 
and 45 w/w % is the degradable matrix between 15 and 45 
w/w % (+/-10%) is the ceramic and between 3-25 w/w % 
(+/-10%) is the PBAE. 
5. The injectable system of claim 1, wherein the system 
comprises 19.5 w/w % degradable matrix, 45.5 w/w % 
solvent, 30 w/w % ceramic and 5 w/w % drug-loaded PBAE. 
6. The injectable system of claim 1, wherein the system 
comprises 18 w/w % degradable matrix, 42 w/w % solvent, 
30 w/w % ceramic and 10 w/w % drug-loaded PBAE. 
7. The injectable system of claim 1, wherein the PBAE is 
pre-loaded with a therapeutic agent, wherein the therapeutic 
agent is selected from the group consisting of coldronate, 
alendronate, etidronate, zoledronate, simvastatin, lovastatin, 
What is claimed: 20 rosuvastatin, SVAK-12, bone morphogenetic proteins, para-
thyroid hormone (1-34), metronidazole, doxycycline, van-
comycin, gentamycin, ciprofloxacin, ketoprofen, celecoxib, 
diclofenac, meloxicam or mixtures thereof. 
1. An injectable system for assisting in osseous tissue 
repair, the system comprising a degradable matrix and 
composite microparticles in a solvent, the degradable matrix 
being selected from the group consisting of PLGA, poly 
(lactic acid) and poly( E-caprolactone) and the solvent being 
selected from the group consisting of N-methyl-2-pyrroli-
done, dimethyl sulfoxide, ethyl acetate, ethyl benzoate, and 
triacetin, wherein the composite microparticles comprise 
cross-linked poly(~-amino ester) (PBAE) microparticles 
embedded with a ceramic, the ceramic being embedded by 30 
dry grinding and the ceramic being selected from the group 
consisting of hydroxyapatite (HA), brushite, calcium poly-
phosphate, ~-tricalcium phosphate, and monetite, and fur-
ther wherein the system solidifies in situ. 
2. The injectable system of claim 1, wherein the degrad-
able matrix is PLGA, with a selected L:G ratio, molecular 
weight, and endcap. 
8. A method of preparing the in situ injectable system of 
25 claim 1, comprising mixing the degradable matrix, 
microparticles and solvent. 
9. The method of claim 8, wherein the microparticles are 
preloaded with at least one pharmaceutical agent. 
10. The method of claim 8, further comprising cross-
linking the degradable matrix. 
11. The method of claim 9, wherein the microparticle are 
mixed with the degradable matrix prior to cross-linking. 
35 
12. A method of treating osseous tissue, comprising 
administering by injection the system of claim 1. 
* * * * * 
